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Abstract 
p53 is a transcription factor activated by genotoxic stress. Dependent on the level of 
DNA damage, p53 can either trigger cell cycle arrest and DNA repair or programmed cell 
death. DNA damaging agents that activate p53 are commonly used in the treatment of cancer. 
If p53 inducible proteins that promote arrest and repair and inhibit apoptosis are up-regulated, 
tumours can become resistant to many types of treatment (multidrug resistance, MDR). MDR 
leads to treatment failure, metastases, and death in breast cancer patients. It is especially 
important in patients who rely solely on chemotherapy because they do not express hormone 
receptors and thus, do not benefit from endocrine therapies (e.g. tamoxifen). We have 
generated a triple-negative doxorubicin resistant breast cancer cell line (CALDOX) and 
shown by RNA array and qPCR analysis that p53-inducible cell survival factor (p53CSV), a 
p53-inducible inhibitor of apoptosis, is up-regulated in CALDOX and inducible by 
doxorubicin. Transient knockdowns of p53CSV sensitised CALDOX cells to doxorubicin, but 
stable knockdowns failed to support this preliminary data. However, CALDOX cells 
maintained expression of arrest and repair proteins p21 and p53CSV at high levels of 
genotoxic stress by doxorubicin—while CAL51 cells induced apoptotic protein p53AIP1 and 
underwent apoptosis. Although it is unlikely that p53CSV acts as a sole factor in MDR in 
CALDOX cells, p53CSV and other p53 arrest and repair proteins are likely an important 
factor in MDR through the evasion of apoptosis and promotion of DNA repair in CALDOX 
cells. Interestingly, we find that p53CSV is widely expressed in normal healthy tissues, 
conserved across eukaryotes, and in CAL51 cells, only partially p53-dependent—indicating 
that p53CSV may have an important role separate of p53, perhaps in the control of 
proliferating cells during development. 
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1. Introduction 
1.1 Breast cancer and multidrug resistance 
Breast cancer was responsible for the deaths of 519,000 people worldwide in 2004, 
and there were an estimated 1.3 million new cases of breast cancer in 2007 (World Health 
Organization, 2006).1-2 In women, it is the most common type of cancer and the second most 
common cause of cancer death. U.S. women have a 1 in 8 chance of developing invasive 
breast cancer during their lifetime, and a 1 in 35 chance of breast cancer causing their death. 
Nevertheless, 5-year survival rates remain at nearly 88% in the U.S., in part due to early 
detection and diagnosis as well as successful endocrine and chemo therapies.2 
Seventy percent of breast cancer patients express and are therefore positive for 
estrogen receptor α.3 ERα is a nuclear receptor that binds to estrogen and regulates gene 
transcription. However, in breast cancer, ERα accumulation causes numerous changes in 
genomic expression, leading to a net effect where mitotic check-points are overridden and 
consequently, uncontrolled cell proliferation occurs.4 Endocrine therapies include anti-
estrogens that specifically targets and inhibits ERα. They are the most popular and successful 
treatment plan for ERα+ tumours. Similarly, breast cancers that are human epidermal growth 
receptor (ErbB-2/HER2/neu) positive are treated with target specific hormone therapies.  
The remaining 10% of breast cancers, which are ER, PgR (progesterone receptor), 
and HER2 negative, are classified as triple negative (TN)—and endocrine therapies are 
unsuccessful in patients with these cancers. TN breast cancer is highly aggressive, and 
despite adjuvant chemotherapy, has a distant metastatis-free survival rate of only 71% after 5 
years.5 TN patients are treated with a chemotherapeutic regimen consisting of several drugs, 
and although the specific regimen is country and physician dependent, typically at least one 
drug is an anthracycline such as doxorubicin (adriamycin) or epirubicin.6 
10 
 
  
Figure 1.1 Schematic overview of multiple mechanisms of multidrug resistance  
(modified from Gottesman et al. 2008)7 
 
Multidrug resistance (relapse) arises when the cancer becomes resistant to a wide 
array of chemotherapeutic drugs—regardless of whether the patient has been previously 
exposed to the drug. Numerous mechanisms at the cellular level have been implicated, and 
resistance in numerous cancer cells lines has been linked to the overexpression of ATP-
binding cassette (ABC) transporters, including P-glycoprotein (Pgp), MRP1, and BRCP1, 
because of their ability to pump drugs out of the cell. Other mechanisms include changes to 
DNA topoisomerase II (a target of anti-cancer anthracyclines), changes in intracellular and 
extracellular tumour pH, and an increase in oxidizing enzymes.8 Apoptotic pathways have 
also been implicated in multi-drug resistance. Up-regulation of anti-apoptotic proteins, such 
as B-cell lymphoma 2 (Bcl-2) and Bcl-extra large (Bcl-xL), or the down-regulation of pro-
apoptotic proteins such as Bcl-2 associated X protein (BAX) and Bcl-2 homologous 
antagonist killer (BAK) can mediate multi-drug resistance in vitro—and phase I/II clinical 
trials using inhibitors against these anti-apoptotic pathways are currently underway.9 Anti-
apoptotic proteins such as p21 that induce cell cycle arrest and DNA repair following 
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genotoxic stress are also potential therapeutic targets.10 Due to the serious nature of TN breast 
cancer and the likelihood of relapse, it is crucial that we understand the mechanisms of 
chemotherapy resistance in TN multidrug resistant cells. Understanding the mechanism 
behind chemotherapy resistance will help to elucidate specific pathways that could be 
targeted in vivo to counter drug resistance in TN patients. 
1.2 The cell cycle 
 The cell cycle is the orderly process by which cells replicate their genetic material and 
divide. There are two general stages: mitosis and interphase. Mitosis occurs when the nucleus 
divides in four subsequent steps: prophase, metaphase, anaphase and telophase. Interphase 
phase is essential for the preparation of cell division and growth, and consists of three phases: 
Gap 1 (G1), Synthesis (S), and Gap 2 (G2).11 During G1, the cell resumes normal biological 
activities following mitosis, growing and preparing for the duplication of DNA during the S 
phase. DNA is replicated during the S phase, and the ploidy of the cell doubles, and other 
biological processes are slowed during this stage. At G2, the cell resumes important 
biological processes that will prepare it for mitosis. Furthermore, cells in G1 can undergo 
temporary arrest, where they do not replicate, entering a stage called G0. However, this 
decision to ―rest‖ must occur before the restriction point, because after this checkpoint has 
passed, the cell is committed to division.12 
 There are multiple ―checkpoints‖ that a cell must proceed through at each stage, to 
ensure accurate replication of DNA and equal division of the cell. Cyclin dependent kinases 
(CDKs) act at these checkpoints, where they must be bound by cyclins in order to 
phosphorylate their downstream targets that trigger progression through the cell cycle.13 
CDKs transcription levels remain stable through the cycle, but transcription of the cyclins 
that bind them vary with the cell cycle and environmental conditions.14-15 CDKs and CDK-
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cyclin complexes can be inhibited by CDK inhibitors (CKIs) in the event of DNA damage, 
genotoxic stress, or oncogene activation.16 
When a cell is signalled to divide, cyclin-dependent kinases 4 or 6 bind to cyclin D, 
which phosphorylates the tumour suppressor retinoblastoma (Rb).17 Rb interrupts the 
inhibition of transcription factors E2F1 and Dp-1, allowing them to induce transcription of 
genes necessary for DNA replication in the S phase (e.g. cyclins A/E).14, 18 Transcription of 
cyclin E allows it to bind to CDK2 and proceed through the G1-S phase transition. During 
and following the S phase, cyclin-CDK checkpoints are passed only when the DNA has been 
accurately replicated, and if necessary, repaired. Cyclin A/B and CDK1 complexes are 
involved in the late G2 and mitotic phases, where they phosphorylate and activate a multitude 
of proteins necessary for mitosis, and induce the assembly of the mitotic spindle and division 
of the nucleus.14 
 
Figure 1.2 Overview of the cell cycle and its regulation by cyclin-CDK complexes 
(modified from Vermeulan et al. 2003)14 
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1.3 p53: “guardian of the genome” 
Transcription of genomic DNA to RNA occurs when RNA polymerase and its co-
factors are recruited to the promoter site of a gene. Transcription factors are nuclear proteins 
that by binding to the promoter site of their target genes either inhibit or induce RNA 
polymerase recruitment and transcription of DNA. The induction of one transcription factor 
can have widespread effects throughout the cell, as most transcription factors bind to and 
regulate a multitude of genes. p53 is a transcription factor that at normal physiological levels 
plays a role in a number of key cellular processes (e.g. cell metabolism, mitochondrial 
respiration, cell adhesion, stem cell maintenance, and development).10 However, p53 is most 
well known as a key regulator in the cellular response to cancer-associated stress signals—
such as DNA damage and oncogene activation. First discovered in 1979, it has been 
nicknamed ―the guardian of the genome‖ for its ability to differentiate between normal and 
neoplastic growth, and to trigger and choose between temporary arrest and DNA repair or 
programmed cell death (i.e. apoptosis) in response to cellular stress. 10, 19-21 
 The p53 family of transcription factors, which includes p53, p63 and p73, stems from 
an ancient family of transcription factors.22-23 p53-like proteins were, until recently, believed 
to be unique to the multicellular Animalia kingdom.24 However, new evidence suggests the 
presence of p53-like proteins and sequences in multiple unicellular protists.22-23 Although the 
original function of p53 is unclear, it is unlikely that p53 arose first as a tumour suppressor. 
Its presence in protists and other simple, short-lived organisms suggests that ancestral p53 
predated the need to suppress uncontrolled cell proliferation. Similarly, early primordial 
organisms would not have had the longevity or size to accumulate genetic mutations 
necessary to induce neoplastic growth. More likely, p53 originally protected immortal germ 
lines against DNA damage and cellular stress in the Cambrian ocean, and it was later co-
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opted for tumour suppression because of its ability to induce DNA repair and apoptosis. 
Interestingly, the ability of p53 to induce cellular arrest (through p21) is unique to 
vertebrates, and p53-independent induction of autophagy and senescence is limited to 
mammals alone.10, 24 
However, this evolutionary heritage has led to two separate, and at times 
contradictory, responses to cellular stress, where a cell either survives and repairs damage, or 
undergoes programmed death. p53 is involved at every stage of cancer. It acts as a tumour 
suppressor in tumourigenesis: cell arrest and repair proteins fix DNA damage before mitosis 
occurs and apoptotic proteins induce cell death in irreparable cells. Both pathways eliminate 
the proliferation of oncogenic cells. Thus, it is unsurprising that tumourigenesis often relies 
on the down-regulation of the apoptotic pathway, and p53 mutations occur in 50% of 
cancers.25-26 However, most p53 mutations are single point (missense) mutations in the DNA 
binding domain and thus, may not abrogate p53 activity completely.27 During the treatment 
of cancer, p53 apoptotic pathways of rapidly dividing cells (e.g. tumour cells, but also cells in 
the gastrointestinal tract, hair follicles, and bone marrow) are targeted through chemo and 
radiation therapies. However, it is at this stage that the two separate pathways of the p53 
response become disparate. p21 and cell repair pathways may help tumour cells recover and 
become resistant to treatments, such as UV radiation and doxorubicin; while pro-apoptotic 
pathways eradicate the tumourgenic cells. Understanding each pathway will be essential for 
restoring drug sensitivity in resistant tumours. 
1.4 Structure of p53 
Human p53 is composed of 393 amino acids, and it forms homotetramers in order to 
bind DNA. Each monomer has five separate domains, each playing an instrumental role in 
p53 function. The N-terminal region contains a trans-activation domain (TAD) that is divided 
into two subdomains (TAD1: residues 1-40 and TAD2: residues 40-61) and also a proline-
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rich region. The TAD binds to proteins that modify the stability and activity of p53, including 
proteins that target p53 for ubiquination and degradation but also co-activators that induce its 
transcriptional function.28 The proline-rich region is poorly understood, but it may act as a 
spacer between the TAD and DNA-binding domains, as its length is crucial for p53-
dependent transcription.29-30 The central DNA binding domain is responsible for the binding 
of p53 to DNA specific sequences of its target genes.31 Near to the C-terminus, the 
tetramerization domain allows for a monomer to bind to another p53 abrogate to form a 
primary dimer, which binds to a second primary dimer—forming an active p53 tetramer that 
binds to and transcribes DNA.32-33 The extreme C terminus regulates p53 activity, down-
regulating or up-regulating its ability to either bind to DNA and its co-factors, through post-
transcriptional modifications and protein-protein interactions.28 
 
 
 
 
 
 
Figure 1.3 The functional domains of human p53. At the N-terminus, the transactivation domain (TAD) is 
necessary for p53 degradation or activation by protein co-factors. The proline-rich domain (PRD) sits between 
the TAD and the DNA binding domain, but its function is poorly understood. The central DNA binding domain 
is responsible for sequence-specific DNA binding of target genes. At the C-terminus post-translation 
modifications regulate p53 activity in the tetramerization domain (TET) and the extreme C-terminus (CT) 
(adapted from Joerger et al.)28 
 
1.5 Choosing between cell cycle arrest and repair, or programmed cell death 
The cell constitutively transcribes p53, but under normal conditions, p53 is down 
regulated at the protein level through ubiquitylation by MDM2—an E3 ubiquitin ligase that 
tags p53 for degradation by the 26S proteosome in the cytoplasm. 
34-37 p53 is activated and up-regulated when DNA damage and other cellular stress signals 
Relative missense mutation 
 frequency in human cancer 
N               TAD              PRD                   central DNA binding domain                                TET        CT             C      
175 
220 
 
245 
248 
249 
273 
282 
1                         61          94              292          325       356           393 
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trigger post-translational modifications of p53 (e.g. phosphorylation, acetylation), inhibiting 
its interaction and degradation by MDM2 and enabling it to promote or inhibit the 
transcription of target genes.38-39 p53 can either induce the transcription of genes known to 
play a role in cell cycle arrest and DNA repair (e.g. p21, GADD45, and 14-3-3-σ) which lead 
to cell survival, or genes that lead to cell death (apoptosis) such as APAF1, p53AIP1, NUMA, 
PUMA, PIG3, and BAX.40 
The choice made by p53 to induce arrest and repair or apoptosis is not only 
determined by its concentration levels, but also by changing its ability to bind apoptotic genes 
versus repair genes, through modifications such as phosphorylation and acetylation, in 
response to particular stress signal. p53 has at least 17 phosphorylation sites, primarily within 
its N-terminus.39 The N-terminus of p53 is necessary for MDM2 binding, but also for binding 
with its transcriptional co-factors. Phosphorylation of p53 by its co-factors is correlated with 
its increased stability and activation, and in many cases, phosphorylation of one or multiple 
sites may be necessary for further post-translational modifications.41 The numerous post-
translational modifications as well as the many kinases that bind each site may represent 
redundant functions to ensure the response of p53, but also suggests the ability for a specific 
and fine-tuned p53 response to a multitude of separate stress signals.39  
p53 is phosphorylated by the ATM kinase at serine 15, and the serine/threonine kinase 
CHK2 acts downstream to phosphorylate serine 20.42-44 These two phosphorylations stabilize 
p53 and allow its binding to promoters of genes that induce G1 arrest and DNA repair.
45 
Other modifications of p53 enhance repair pathways too. At the carboxy-terminal lysine 
(Lys) 320 can be acetylated by the acetyltransferase PCAF and promotes p53-dependent 
growth arrest through the recruitment of co-activators to the promoter site, such as CREB-
binding protein (CBP) and TRRAP.38  Acetylated lysine 320 p53 binds more efficiently to 
p21 than non-acetylated p53, and in mice, a single point mutation at 317 (the mouse 
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equivalent of lysine 320) induces p53-dependent transcription of pro-apoptotic target genes 
NOXA and PUMA.46-47 Similarly, ubiquitination at Lys 320 by the ubiquitin ligase E4F1 
induces the transcription of cell cycle arrest and DNA repair proteins such as p21, Gadd45, 
and cyclin G1, but not of apoptotic proteins. Similarly, on a mechanistic level, p53 
ubiquitylated at serine 320 binds to the promoter of p21, but not to the apoptotic gene 
NOXA.45, 48 
Numerous modifications of p53 have also been implicated in the apoptotic pathway. 
Phosphorylation of serine 46, for example, promotes the induction of the p53-regulated 
apoptosis-inducing protein 1 (p53AIP1) and downregulates the expression of p21—leading to 
p53 dependent programmed cell death.49 Acetylation of Lys 373 by p300/CBP enhances 
phosphorylation at the N-terminus, which helps to stabilize p53 and allows it to bind to 
promoters of pro-apoptotic genes including PIG3, BAX, and p53AIP1.45-46 Acetylation at 
lysine 120, in the DNA binding region of p53, also enhances p53’s ability to bind to and 
transcribe apoptotic genes (e.g. PUMA and BAX)—and Lys 120 mutants have trouble 
inducing apoptosis, but their ability to induce cell arrest remains intact.50  
Human p53 binds to target genes at a p53 sequence specific site called a p53 response 
element (RE). The location of the RE to the transcription start site is likely significant in p53-
dependent transcription, as 50% of established REs are located in the promoter region of a 
gene, and approximately 25% are located in the first intron.51 However, there is evidence that 
p53 binding sites also exist large distances from the start site. Many p53 post-translational 
modifications exert their effect by changing the way p53 binds to its target genes at their RE. 
RE sequences vary between genes, and determine a target gene’s affinity for p53 binding. 
The accepted consensus sequence contains two 10-base decamers and a spacer: 
RRRCWWGYYY…n(0-2)…RRRCWWGYYY (R is a purine, Y is a pyrimidine, W is an A 
or T).52 Each p53 unit of the p53 tetramer binds to three of nucleotides within the RRRCW or 
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WGYYY pentamers, causing conformational changes to the DNA and p53 monomers. 
However, some studies suggest that p53 can bind to REs with longer spacers (as many as 13), 
or with half or three-quarter sites.53 Genes associated with the arrest and repair pathway 
typically have high affinity REs that respond to lower levels of p53. Pro-apoptotic genes 
generally contain low affinity REs that are activated following high levels of genotoxic stress 
and increased concentrations and modifications to p53.52 
In addition to post-translational modifications and varying affinity to target gene REs, 
the choice between arrest and repair or apoptosis can be made by which of many co-factors 
are present to bind to p53. Co-factors influence promoter-selective p53 transcription and 
post-translational modifications can alter which co-factors can bind to p53. For example, p53 
can recruit a number of co-factors that induce the transcription of pro-apoptotic genes and 
repression of cell cycle arrest, including prolyl isomerase PIN1, cellular apoptosis 
susceptibility protein (CAS), and transcription factors such as NF-κB, p63, and p73.54-56 
These factors can act at multiple levels, and can be involved in recruitment of p53 to 
promoters, in post-translational modification of p53, and in the inhibition or stabilization and 
activation of p53. PIN1 for example, is recruited to chromatin by p53 and allows p300 to 
acetylate p53 and induce the transcription of pro-apoptotic genes. Furthermore, PIN1 helps 
p53 dissociate from the apoptosis inhibitor (iASPP) after the phosphorylation of serine 46.54  
In contrast, at low levels of stress, p53 can interact with co-factors that promote transcription 
of cell cycle arrest and DNA damage repair, such as Y-box factor 1 (YB1), hematopoietic 
zinc-finger (HZF), or co-factors that inhibit apoptosis (e.g. iASPP).52  
1.6 p53CSV: a novel gene with a role in the p53 pathway 
In 2005, Park and Nakamura reported a new gene, p53-inducible cell survival factor 
(p53CSV), which they identified in cells subjected to UV radiation or doxorubicin 
treatment.57 p53CSV is a small protein (8786 daltons) that consists of 76 amino acids. In p53-
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/- cell lines, Park and Nakamura claimed that p53CSV was not induced following genotoxic 
stress, and although this was largely the case, their data suggested the possibility of some 
p53-independent induction of p53CSV. However, subsequent studies have suggested, but 
failed to test, alternative RE sites nearer to the transcription start site; and the transcriptional 
regulation of p53CSV by p53 remains poorly understood.58 Nevertheless, p53CSV was much 
more strongly induced in p53 wild type (wt) cell lines. Furthermore, Park and Nakamura 
identified a putative p53 binding site in exon 2 and confirmed binding in vitro with chip 
analysis and a luciferase reporter assay. The down-regulation of p53CSV in p53wt cell lines 
increased the percentage of apoptotic cells following treatment with either UV radiation or 
doxorubicin, while stable overexpression of p53CSV in p53-/- cells decreased the percent of 
apoptotic cells following treatment with UV radiation or doxorubicin.57  
Because p53CSV prevented apoptosis but was induced by p53, they postulated that it 
played a role in the cellular arrest and repair pathway. In support of this hypothesis, they 
found that when the arrest and repair pathway was activated, determined by the expression of 
p21 and phosphorylation of p53 serines 15 and 20, p53CSV was highly expressed. Moreover, 
when apoptosis was induced, confirmed by the expression of apoptotic protein p53AIP1, 
phosphorylation of p53 serine 46, and down-regulation of p21, p53CSV was not expressed. 
Co-immunopreciation experiments with a p53CSV antibody determined that p53CSV bound 
to apoptotic protease activating factor 1 (Apaf-1) and heat shock protein 70 (Hsp70). Apaf-1 
is a protein that cleaves pro-caspase 9 to become caspase-9, which triggers downstream 
caspases (e.g caspase-3) and apoptosis. Hsp70 is a protein that helps to mediate cellular 
stress, and in the case of Apaf-1, it inhibits its function and prevents apoptosis. The authors 
found that in p53-/-  cells expressing p53CSV, cleavage of pro-caspase-9 decreased following 
genotoxic stress compared to those cells that did not express p53CSV—confirming a role for 
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p53CSV in the arrest and repair pathway by inhibiting apoptosis in order to give the cell time 
to repair DNA damage.57  
p53CSV remains largely unstudied. A recent in vitro study found that p53CSV is up-
regulated following camptothecin treatment in two separate glioblastoma cell lines; however, 
both cell lines ultimately progressed to senescence or apoptosis, and the screenings failed to 
discern whether p53CSV was induced as part of the early or late stress response.59  
p53CSV has also been found to be up-regulated in several genomic screenings of 
human cancers. In a cohort of 50 patients with multiple melanoma, p53CSV was upregulated 
in 50%.60 In patients with follicular lymphoma, p53CSV and other p53-inducible genes were 
up-regulated following irradiation treatment.61 However, as both anti- and pro-apoptotic 
genes were induced, we can only infer that p53CSV plays a role in the p53 response, but not 
as what stage, following irradiation in vivo. In patients with AML, p53CSV was up-regulated 
shortly after the administration of chemotherapy, but again, both anti- and pro-apoptotic p53-
dependent genes were up-regulated in this screening, and a role for p53CSV in the arrest and 
repair or the apoptotic pathway could not be distinguished in vivo.62  
Another screening found that p53CSV was part of a ―Poised Gene Cassette‖ of 48 
genes that experience tighter regulation and less variance in six different tumour types 
compared to non-malignant controls.63 Although this suggests that p53CSV plays an 
important role in tumours, these authors found that silencing p53CSV increased invasion in 
HCT116 cells—likely increasing their metastatic potential. However, such tight regulation in 
cancer suggests that the protein is carefully balancing two disparate pathways, and it is 
possible that p53CSV plays a negative role in invasion, but a pro-survival pathway in 
response to therapy.63 Recently, p53CSV was found to be expressed in all breast cancer cell 
lines.64 
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Interestingly, p53CSV is highly conserved in vertebrates (Table 1.1, Appendix A for 
full sequences) and has orthologs in X. laevis, C. elegans, S. cerevisieae and A. thaliana 
(Appendix A). MDM35, the p53CSV ortholog in budding yeast, was shown to mediate 
doxorubicin resistance.65 Its high level of conservation suggests that p53CSV has an essential 
role in eukaryotic cells, perhaps as part of the cell’s response to genotoxic stress. 
Table 1.1 Conservation of p53CSV in vertebrates 
Organism Amino Acid Sequence (51-76) 
Human AIKEKEIPIEGLEFMGHGKEKPENSS 
Chimpanzee AIKEKEIPIEGLEFMGHGKEKPENSS 
Dog AIKEKEIPIEGLEFMGHGKEKPESSS 
Cow AIKEKEIPIEGLEFMGHGKEKPESSS 
Mouse AIKEKEIPIEGLEFMGHGKEKPENSS 
Rat AIKEKEIPIEGLEFMGHGKEKPENSS 
Chicken AIKEKDIPIEGLEFMGPSKGKAENSS 
Zebra Fish AIKEKDIPIEGVEFMGPNSEKADS - - 
  
In summary, p53CSV is likely to play an important role in the p53 arrest and repair 
pathway. Previous data suggests that it assists cells in surviving low doses of irradiation or 
chemotherapy treatment. Thus, it may play a role in the development of MDR in vivo, and 
could be a potential target for restoration of drug sensitivity. However, its role in the p53 
response pathway remains poorly understood, and further studies are necessary. 
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2. Preliminary Work 
CAL51 is a triple-negative breast cancer cell line originally derived from a malignant 
pleural effusion of a 45-year old patient with invasive adenocarcinoma with extensive 
intraductal involvement. It is epithelial, clonogenic in soft agar, and tumourigenic in nude 
mice. It has a normal diploid karyotype and it is phenotypically negative for ER, PgR, and 
ERBB2—making it a good cell model to study TN breast cancer chemotherapy resistance.66-
67 
Dr. E Yagüe and his laboratory, in collaboration with Dr. S Raguz, generated a 
doxorubicin resistant CAL51 derivative (CALDOX) by selection of CAL51 cells in the 
presence of 0.4 μM doxorubicin. Although microscopically indistinguishable from CAL51, 
CALDOX cells have a slower proliferation rate than their parental progenitor. Yagüe and 
colleagues determined 400 genes which were differentially expressed in CALDOX cells by 
Affymetrix hybridization. They compared these to the changes in genomic DNA between 
CALDOX and CAL51 cell lines, as determined by Comparative Genomic Hybridization 
(CGH), performed by Dr. Nigel Carter’s group at Cambridge University. Of these 400 genes, 
ten that had been previously associated with chemotherapy resistance in other cell lines were 
selected for further investigation. Transient down-regulation by siRNA or up-regulation by 
cDNA expression was performed in CALDOX cells (Table 2.1). Controls were obtained by 
transfection of either empty cDNA expression vectors, or EGFP siRNA. The drug response 
of the transfected cells was examined by sulforhodamine B staining (SRB).68 Although genes 
such as catalase, metallothionein, and glutathione peroxidise, all of which were 
overexpressed in CALDOX cells and have been previously associated with doxorubicin 
resistance, their experimental down-regulation with siRNA did not change CALDOX cells’ 
sensitivity to doxorubicin.69-71 In contrast, down-regulation of p53CSV, also overexpressed in 
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CALDOX, increased CALDOX cells sensitivity to doxorubicin as an increase in cell death 
upon exposure to doxorubicin was observed (Figure 2.1).  
 
Table 2.1 Changes in drug sensitivity following experimental up or down regulation of candidate 
genes obtained from the Affymetrix array analysis 
Gene Product Expression 
in CALDOX 
Strategy Change in Drug 
Sensitivity 
BCAT1 Amino acid transporter Up RNAi No 
MT1M Metallothionein Up RNAi No 
p53CSV Anti-apoptotic Up RNAi Yes 
CAT Catalase Up RNAi No 
GPX1 Glutathione peroxidase Up RNAi No 
EMP1 Epithelial membrane protein 1 Down Overexpression No 
SLC2A3 Glucose transporter Down Overexpression No 
 
 
 
 
 
 
 
Figure 2.1 Transient knockdown of p53CSV sensitises CALDOX cells to 
doxorubicin. CALDOX cells were transiently transfected with a siRNA targeting 
p53CSV mRNA and then left to grow for 4 days in the presence of 0.4 µM 
doxorubicin. Change in cell numbers were determined by SRB growth assays. A 
siRNA targeting EGFP mRNA, a protein absent in human cells, was used as a 
negative control. CALDOX cells transfected with transient siRNA against p53CSV 
were more sensitive to and grew more slowly in 0.4 μM doxorubicin than cells 
transfected with control siRNA against EGFP (at 2 and 4 days). Data represents a 
single experiment with 3 internal replicates ± SD. Values are expressed relative to 
the absorbance obtained from cells growing in the absence of doxorubicin. 
 
As previous studies implicated p53CSV in the p53 arrest and repair pathway, it was 
important to better understand the role of p53 in CALDOX and CAL51 cells. Western blot 
data indicated that the apoptotic pathway, measured by the presence of acetylated p53, was 
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induced at lower doses (0.05 μM+) of doxorubicin in CAL51 cells than in CALDOX cells—
where acetylated p53 was only detected at high (10 μM) concentrations (Figure 2.2). 
Furthermore, p21, indicative of the arrest and repair pathway, appeared to be constitutively 
activated in CALDOX cells, as it was present with or without the addition doxorubicin. In 
contrast, although p21 was induced at low levels of damage in CAL51 cells, by 10 μM it had 
been completely down-regulated as CAL51 cells underwent apoptosis. This was not the case 
in CALDOX cells, where p21 also remained active at high doses of genotoxic stress.  
CAL51  CALDOX 
0 0.05 0.1 1 10  0 0.4 1 10 
(μM doxorubicin)  (μM doxorubicin) 
p21 (21 kDa) 
 
Acetylated p53 (53 kDa) 
 
Beta Actin (43 kDa) 
 
 
Figure 2.2 The expression of p53 and p21 differs between CALDOX and CAL51 cells. Protein 
levels of p21 and acetylated p53 in CALDOX and CAL51 cells at increasing concentrations of 
doxorubicin (0 – 10 μM) were determined by western blot analysis. p21 (indicative of the arrest and 
repair pathway) was expressed at all concentrations in CALDOX cells, but in CAL51 cells it was only 
induced at low concentrations of doxorubicin (0 – 1μM). Acetylated p53 (indicative of the apoptotic 
pathway) was expressed in CAL51 cells at all doses (0.05 – 10 μM) but was only induced at 10 μM in 
CALDOX cells. β-actin is used as a loading control. 
 
In addition, caspase activity assays showed that caspase 9 and downstream caspases 3 
and 7 were induced at low levels of stress in CAL51 cells, and that activity plateaued 
between 1 and 10 μM of doxorubicin (Figure 2.3). Caspases are involved in the early stages 
of apoptosis, and their high activity at low doses of genotoxic stress supports our hypothesis 
that CAL51 undergoes apoptosis earlier than CALDOX. CALDOX cells, despite an 
unexplained peak in activity at 0 μM, had low levels of caspase activity at low doses of 
doxorubicin, and activity increased but remained low at 10 μM doxorubicin.  
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Figure 2.3 Activation of caspases in CAL51 and CALDOX cells following 
doxorubicin treatment is different. Apoptotic activity in CAL51 and CALDOX 
cells was measured using Caspase-glo activity assays following genotoxic stress by 
doxorubicin (0 – 10 μM). Higher levels of caspase 9 (a) and caspases 3/7 (b) activity 
were observed in CAL51 cells than in CALDOX cells following treatment with 
doxorubicin. 
 
 Cell cycle analysis with fluorescence-activated cell sorting (FACS) showed a higher 
percentage of cells at G1 in CALDOX cells than in CAL51 cells (Figure 2.4). When 0.4 μM 
doxorubicin was added for either 24 or 48 hours, the number of cells at the G1 checkpoint did 
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not significantly change in CALDOX cells, while in CAL51 cells many cells underwent 
apoptosis (evidenced by the increasing sub-G1 population in P4) or entered G2 arrest.  
 24 hr 48 hr  
0 μM doxorubicin 0.4 μM doxorubicin 0.4 μM doxorubicin  
   
CAL51 
   
CALDOX 
Figure 2.4 CALDOX cells remain in G1 while CAL51 undergo G2 arrest and apoptosis following 
treatment with doxorubicin. Cell cycle analysis by flow cytometry was performed in CALDOX and 
CAL51 cells treated with 0 μM or 0.4 μM doxorubicin for 24 and 48 hours. P4: cells in sub-G1; P5: cells 
in G1; P6: cells in S; P7: cells in G2. A larger percent of CALDOX cells were observed at the G1 
checkpoint than in CAL51. In response to doxorubicin at 24 and 48 hours, a large percent CAL51 cells 
underwent G2 arrest or apoptosis (sub-G1); meanwhile, CALDOX cells did not alter their cell cycle 
profile. 
 
 
Lastly, because P-glycoprotein and other ABC transporters are well known for their 
role in multi-drug resistance, we ruled out the possibility of efflux pumps in mediating MDR 
in CALDOX cells. Flow cytometry experiments showed that fluorescent antibodies against 
Pgp did not bind to CALDOX or CAL51 cells (Figure 2.5a). Additionally, Calcein AM-
Efflux, an assay where Calcein AM, a non-fluorescent transporter substrate, that fluoresces 
when cleaved by intracellular esterases, also indicated the absence of a cyclosporin-
inhibitable pump in CALDOX cells (Figure 2.5b). Lastly, doxorubicin, which is naturally 
fluorescent, accumulated to the same extent in both CAL51 and CALDOX cells after 1 hr—
Sub-G1    G1      S        G2            
(phase) 
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but did not accumulate in NCI cells (positive control cells expressing Pgp, Figure 2.5c). Thus, 
we confirmed that drug resistance in CALDOX cells is not mediated by a known transporter. 
Surface P-glycoprotein Calcein AM-Efflux Doxorubicin Accumulation  
   
CAL51 
 
  
CALDOX 
  
 
NCI/ADR-Res 
(positive control) 
 
Fluorescence  
Figure 2.5 Absence of efflux pumps in CALDOX cells. A. Flow cytometry analysis of Pgp 
expression using the UIC2-phycoerythrin-conjugated antibody (filled peaks) and the corresponding 
IgG isotype control (clear peak). In CAL51 and CALDOX cells, these peaks overlap, indicating that 
Pgp is not present in the cellular membrane. Pgp positive NCI-ADR-Res cells were used as a positive 
control. B. Flow cytometry analysis of calcein-AM efflux. Cells that were incubated in the presence of 
a pump inhibitor (cyclosporin A, filled peaks) produced a fluorescent peak as they could no longer 
efflux the fluorescent substrate. AF, autofluoresecnce. In CAL51 and CALDOX cells, the presence of 
CsA did not affect the intracellular concentrations of calcein, indicating the absence of membrane 
pumps. NCI/ADR-Res cells were used as a positive control. C. Flow cytometry analysis of intracellular 
accumulation of doxorubicin. Cells were incubated in 0.4 μM doxorubicin for 15 minutes. In CAL51 
and CALDOX cells, doxorubicin accumulates intracellularly and the cells fluoresce (filled peaks). 
NCI/ADR-Res positive controls did not fluoresce as they pumped out the fluorescent drug. 
 
 
 In summary, our previous data suggested that doxorubicin resistance in CALDOX 
cells was due to their ability to inhibit and evade apoptosis and induce the p53-dependent 
cellular repair pathway. Transient knock-down of p53CSV indicated that this protein was 
important for resistance in CALDOX, and we postulate that it plays a role in inhibiting 
apoptosis, allowing for DNA repair by p21, in response to genotoxic stress. 
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3. Methods and Materials 
3.1 Cell line maintenance 
Breast cancer cell lines CAL51, MCF7, and CALDOX were grown in low glucose 
GIBCO Dulbecco’s Modified Eagle Medium (DMEM) with GlutaMAX-1 (Invitrogen) 
containing 10% fetal calf serum, and 1% Antibiotic Antimycotic Solution (Invitrogen). In 
addition, CALDOX was maintained in media containing 0.4 μM doxorubicin. The estrogen-
independent MCF7 derivative cell line, MLET5, was grown in phenol red free, low glucose 
GIBCO DMEM (Invitrogen) supplemented with 10% FCS, 2 mM L-glutamine and 1% 
Antibiotic Antimycotic Solution. 
3.2 RNA extraction 
Cells were trypsinized, washed with PBS (phosphate buffer saline), centrifuged, and 
stored at 80C until further use. Frozen cell pellets were thawed by the addition of 450 μL 
of RNAzol (Biogenesys, Poole, United Kingdom) and 50 μL of chloroform. Pellets were 
resuspended by gentle mixing with a Pipetman followed with vigorous mixing by a vortex for 
15 seconds. Samples were stored on ice for 15 minutes and then spun at 17,000 g for 15 
minutes at 4C. The aqueous upper phase containing RNA was carefully collected and 
transferred to a fresh tube where an equal volume of isopropanol was added. The homogenate 
was inverted several times and left on ice for 15 minutes. Samples were then spun for 15 
minutes at 17,000 g at 4C; and the supernatant was removed and the RNA pellet washed 
with 70% ethanol. Samples were left to dry on ice before being resuspended in 30 μL of 
Analar autoclaved water. The RNA pellet was rehydrated for 1 hr on ice. The sample was 
mixed by pipetting and the RNA concentration was measured using a NanoDrop 
spectrophotometer (ND-1000, Thermo Scientific). RNA was stored for short periods at 
20C, but for long-term storage it was kept at 80C. 
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3.3 Reverse transcription: preparation of cDNA 
Reverse transcription reactions were performed with sterile filter tips (StarLabs) and a 
First Strand cDNA Synthesis Kit for RT-PCR (AMV, Roche Applied Sciences). To each 10 
μL reaction, 0.4 μL (≥10 units) AMV reverse transcriptase, 1 μL of  1.6 μg/μL random 
hexamers, 1μL of 10 mM dNTPs, 2 μL of 25 mM MgCl2, 1 μL of 10x reaction buffer, 1 μg of  
sample RNA and Analar autoclaved water (as necessary, to make 10 μL) were added. 
Samples were incubated at 42C for 1 h and the reverse transcriptase was then denatured by 
incubation 95C for 5 min. Once cool, cDNA was diluted in 90 μL of Analar autoclaved 
water to a final concentration of approximately 10 ng/μL.   
3.4 Quantitative PCR 
Quantitative PCR (qPCR) reactions were prepared with a SensiMix SYBR Kit 
(Bioline) and sterilized filter tips (Starlabs) on MicroAmp Fast Optical 96-well reaction 
plates (Applied Biosystems) in a PCR laminar air flow cabinet. For each gene, a master mix 
containing 50 μL SensiMix, 2 μL SYBR Green, and 0.5 μL of 100 μM of each primer (i.e. 
forward and reverse) was prepared. To each well 5 μL of cDNA and 5 μL of master mix were 
added. For standard curves, 0%, 1%, 10%, and 100% neat cDNA of either untreated CAL51 
or CALDOX cDNA was prepared and aliquoted into appropriate wells. Standards were 
prepared by serial dilution using sterile Analar water. All samples and standards were 
performed in triplicate. For each experiment, a minimum of two normalisers were included in 
order to account for the varying amounts of cDNA between samples.   
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Table 3.1 Primer Sequences for qPCR 
Gene Amplified Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
p53AIP1 CACAGATGTGCAGGAGGAGA TCACCGAGAGGTTCTGGTCT 
p21 CCTGTCACTGCTTGTACCCT GCGTTTGGAGTGGTAGAAATCT 
p53CSV AGGATTTCGCAAGTCCAGAA GCTGATTCCACCCAAGTAT 
RPLP0 GGCGACCTGGAAGTCCAACT CCATCAGCACCACAGCCTTC 
RPS6 AGGGTTATGTGGTCCGAATCA TGCCCCTTACTCAGTAGCAGG 
RPS14 TCACCGCCCTACACATCAAACT CTGCGAGTGCTGTCAGAGG 
18S CGGCTACCACATCCAAGGAA GCTGGAATTACCGCGGCT 
 
Reactions were performed on a 7900 Fast Real-Time PCR System (Applied 
Biosystems). Primers were selected by their ability to amplify under the pre-determined 
reaction conditions (95C 10 m hot-start, followed by 40 cycles: 95C 30s denaturation step, 
60C 30s annealing step, 72C 30s elongation step), and primer sequences are listed in Table 
3.1. Dissociation curves were run for each primer set (Table 3.1) to make certain that primer 
dimers did not form and prevent the accurate quantification of cDNA.  
3.5 Quantitative PCR (qPCR) analysis 
 Quantitative PCR analysis was done with SDS 2.3 Taqman software. The cycle 
threshold (Ct) values were manually set to the steepest part of the amplification slope and 
outlying wells were omitted from data analysis. Standard curves, mean DNA quantities, and 
standard deviations were calculated by the Taqman software. In order to account for varying 
amounts of cDNA between RNA samples (e.g. CALDOX and CAL51), the gene of interest 
in each sample was divided by a house-keeping gene (i.e. ―normaliser‖) from that sample 
(Equation 3.1). Standard deviations of these ratios were calculated using Excel (Equation 
3.2). Ratios were used to compare the expression of the gene of interest across multiple test 
conditions (e.g. between cell lines, or at different drug concentrations).  
Equation 3.1 
                                            
                                      
                                            
 
Equation 3.2 
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3.6 Drug assays 
Cells (2000-4000) were seeded in 200 μL of medium per well in flat-bottomed 96-
well plates. In stable cell lines, the antibiotic used for selection (i.e. G418 or puromycin) was 
added, but for CALDOX cells, the medium was doxorubicin free. The cells were permitted to 
adhere to the plate for 24 hours. The following day, the medium was removed and 200 μL of 
medium containing the experimental conditions (e.g. drug(s) at various concentrations) was 
added. In stable cell lines, cells continued to be grown in the presence of their selection factor 
throughout the experiment. Each condition (i.e. drug concentration) was performed with six 
replicates.  
Cells were left to grow in the presence of the drug(s) for approximately three doubling 
times before a sulforhodamine B (SRB) colourimetric assay was performed.68 In some 
experiments, time points were collected by seeding the plates in triplicate, and performing an 
assay at days 0, 2 and 4. Cells were first fixed by adding 100 μL of ice-cold 40% (w/v) 
trichloroacetic acid (TCA) to each well. After 1 hr, the TCA was removed by gentle washing 
under running tap water. Once the plate had been washed five times, 100 μL of SRB was 
added to each well, in order to bind with intracellular proteins, for 30 minutes. Excess SRB 
dye was removed by carefully washing the plates five times with 1% (v/v) acetic acid. Plates 
were left to air-dry for 2-3 days. SRB was solubilized by adding 100 μL of 10 mM Tris-base 
and leaving the plate on an orbital shaker for 30 minutes. Blank samples were prepared by 
pipeting 100 μL of 10 mM Tris-base into several empty wells on each plate. Absorbance was 
measured at 492 nm by a Tecan Sunrise microplate reader (Tecan Group Ltd.). 
3.7 RNA interference: transient transfections 
CALDOX (1x105) cells were seeded in flat bottomed 6-well plates and left to adhere 
overnight. Cells were grown in medium under normal conditions. The next day, transient 
knock-downs were prepared by sequentially adding neat media (without FCS or antibiotic), 
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HiPerFect transfection reagent (Qiagen), and siRNA (EGFP from Ambion, p53CSV from 
Dharmacon) to an eppendorf tube and leaving the reaction to incubate for 10 minutes. 
Concentrations of siRNA and HiPerFect are listed in Table 3.2. p53CSV siRNA is a mixture 
of 4 siRNAs targeting different regions of the p53CSV mRNA. Media was removed from the 
6 well plates and cells were resuspended in 2.3 mL neat media. The 100 μL siRNA reactions 
were added drop-wise to each well. One control well received HiPerfect without siRNA and 
another control received neither HiPerFect nor siRNA.  
The cells were left to incubate with siRNA for 24 hours. Cells were washed with PBS, 
trypsinised, and counted using an haemocytometer. Treated cells were seeded (6000 per well) 
with six replicates in 3 flat-bottomed 96 well plates. On one plate, cells were resuspended in 
normal medium (containing FCS and antibiotic), but without drug. This plate was named day 
0, and an SRB assay was performed after 24 hours, once the cells had adhered to the plate. 
On the two remaining plates, treated CALDOX cells (control, control with HiPerfect, EGFP 
siRNA cells, p53CSV siRNA cells) were resuspended in 0.4 μM doxorubicin in normal 
medium. These plates were left to incubate for 2 and 4 days before an SRB assay was 
performed (see drug assays). 
Table 3.2 SiRNA Reagents and concentrations 
Reagent 50 μM EGFP siRNA 
(Ambion) 
p53CSV siRNA smartpool 
(Dharmacon) 
Neat media (μL) 86.1 83.2 
HiPerFect (μL) 12.0 12.0 
siRNA (μL) 1.92 4.80 
 
3.8 RNA interference: stable transfections 
Small hairpins targeting p53CSV mRNA and a scrambled mRNA that acted as a 
negative control were cloned into pGFP-V-RS from OriGene (catalogue #TG318755, Figure 
3.1). DNA preparations from the above plasmids were performed using a Maxiprep kit 
(Qiagen). Retroviral transfections were performed by Dr. Selina Raguz (MRC) following 
standard protocols. In brief, retroviral supernatants of infected HEK293T cells (transfected 
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with retroviral plasmid and helper virus using polyethylenimine) were added to CALDOX 
cells and stably transfected cells selected by puromycin (0.5 µg/mL) resistance. Stable 
CALDOX lines expressing small hairpins to p53 and p21 were generated in the same way by 
Dr. Selina Raguz. 
 
Figure 3.1 Vectors used in stable p53CSV knockdown in CALDOX cells. Small 
hairpin RNAs targeting p53CSV or a scrambled negative control were cloned into 
PGFP-V-RS (Origene, catalogue number #TG318755). 
 
 
3.9 Overexpression of p53CSV in CAL51 cells 
  
Figure 3.2 Vectors used in p53CSV overexpression in CAL51 cells. A. p53CSV cDNA was 
cloned into vector pCMV6-AC-GFP by Origene. B. Vector pEGFP-N1 expresses EGFP cDNA 
and was obtained as a negative control. 
 
p53CSV (513, pCMV6-AC-GFP, Origene, Figure 3.2a) and EGFP plasmids (D161, 
pEGFP-N1, Clonetech Laboratories, Figure 3.2b) were linearised with ScaI and ApaLI, 
respectively, and confirmed by gel electrophoresis. Linear DNA was purified by phenol-
A.      B. 
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chloroform extraction. First, the linearised DNA was made up to 400 μL with Tris EDTA 
(TE) buffer and 400 μL of phenol-chloroform was added in order to denature the restriction 
enzymes from the previous digestion step. The samples were vortexed vigorously for 15 
seconds, incubated on ice for 5 minutes and then centrifuged at 17,000 g for 15 minutes at 
4C. The homogenate had separated into two separate phases, and the top, aqueous layer 
containing DNA was transferred to a new Eppendorf tube—great care was taken not to 
disturb the interphase which contained denatured protein. To the aqueous phase, 1/10 volume 
of 3 M NaCl and 2.5 volumes 100% ethanol were added. After gently mixing with a 
Pipetman, the samples were left at 20C for 30 minutes. The DNA was centrifuged at 
17,000 g for 15 minutes at 4C. A DNA pellet was observed and washed with 500 μL of 70% 
ethanol. The ethanol was removed and the pellet was left to dry in a sterile tissue culture 
hood. When all ethanol droplets had evaporated, the pellet was resuspended in 60 μL of 
sterile Analar water. The DNA concentration was measured using a NanoDrop 
spectrophotometer (ND-1000, Thermo Scientific). DNA was stored at 20C. 
CAL51 cells were trypsinized, counted, and seeded (800,000 cells) in 4 x 25 cm2 
flasks, in 10% FCS GIBCO DMEM with GlutaMax (Invitrogen) without antibiotic. Cells 
were permitted to adhere to the flasks for 24 hours. Next, in one Eppendorf tube, 24 μg of 
purified linear EGFP or p53CSV cDNA was incubated in 1.8 mL of neat DMEM for 5 
minutes. In a second Eppendorf tube, 72 μL of Lipofectamine transfection reagent 
(Invitrogen) was simultaneously incubated in 1.8 mL of neat DMEM. The two were gently 
mixed in a 15 mL Falcon tube and incubated at room temperature for another 20 minutes. 
Cells were then resuspended in this new mixture, with two replicates for each gene (i.e. 
EGFP and p53CSV). Cells were left in this suspension overnight, and an additional 3.6 mL of 
antibiotic-free media, but containing 20% FCS, was added to each flask. Three days after the 
addition of Lipofectamine and cDNA, each flask was passaged and cells were resuspended in 
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medium containing 10% FCS and antibiotic. In the next passage, G418 (700 μg/mL, Sigma) 
was added and the formation of numerous colonies was observed after approximately 2-3 
weeks. Colonies were mixed in the next passage and stably transfected pools of cells were 
maintained in 350 μg/mL G418. 
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4. Results 
4.1 Expression of p53CSV in CALDOX and CAL51 cells 
Previous RNA array data indicated that p53CSV was overexpressed in CALDOX cells 
compared to CAL51 (1.48 fold, 2.33 fold in doxorubicin). We sought to confirm this data 
using qPCR. CALDOX (grown in 0.4 µM doxorubicin) and CAL51 cells were harvested and 
RNA extractions, reverse transcription reactions, qPCR with two normalisers, 18S ribosomal 
RNA (18S) and Ribosomal protein S6 (RPS6), were performed (Figure 4.1). CALDOX cells 
were found to overexpress p53CSV by 1.76-2.73 fold compared to CAL51 (p<0.001). 
 
Figure 4.1 p53CSV is up-regulated in CALDOX cells. RNA was extracted from 
CALDOX cells grown in 0.4 μM doxorubicin and from untreated CAL51 cells. 
qPCR measured p53CSV RNA levels that were normalised with expression levels 
of 18S and RPS6. Data represents a single experiment with 4 internal replicates (± 
SD). Experiment was twice repeated with similar results (data not shown). 
 
 
4.2 Transient knock-down of p53CSV in CALDOX cells 
            In a previous experiment that transiently knocked-down p53CSV expression in 
CALDOX cells, an increase in sensitivity to doxorubicin after 2 and 4 days was observed. 
We repeated this experiment, using the same siRNAs (a 4 siRNA cocktail, as described in 
methods and materials), to knock-down p53CSV in CALDOX (Figure 4.2). Following 2 and 
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4 days in 0.4 µM doxorubicin, CALDOX cells transfected with p53CSV siRNA grew 
significantly less (64% and 66%, respectively) than those transfected with control EGFP 
siRNA (both p<0.0001). We repeated the experiment with similar results (data not shown). 
From this data, we confirmed that transiently knocking down p53CSV partially re-sensitised 
cells to doxorubicin. 
 
Figure 4.2 Transient knockdown of p53CSV sensitises CALDOX cells to 
doxorubicin. CALDOX cells were transiently transfected with a siRNA targeting 
p53CSV mRNA and then left to grow in the presence of 0.4 µM doxorubicin. 
Changes in cell numbers were determined by SRB growth assays. siRNA 
targeting EGFP mRNA, which is absent in human cells, was used as a negative 
control. CALDOX cells transfected with transient siRNA against p53CSV were 
more sensitive to and grew more slowly in 0.4 μM doxorubicin than cells 
transfected with control siRNA against EGFP (at 2 and 4 days). Data represents a 
single experiment with 6 internal replicates ± SD. Values are expressed relative to 
the absorbance obtained in cells transfected with EGFP siRNA. 
 
4.3 p53CSV is up-regulated in CALDOX cells in the absence of doxorubicin 
Our RNA array and qPCR data indicated that p53CSV is up-regulated in CALDOX 
cells. As cells were grown in the absence of doxorubicin for five days prior to the array, it is 
likely that p53CSV plays a role in resistance separately of the immediate response to the 
drug. We grew CALDOX cells in the absence of doxorubicin for 5, 23, and 38 passages 
(approximately 15, 69, and 114 days). RNA was extracted from these cells in addition to  
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Figure 4.3 p53CSV is up-regulated in CALDOX cells in the absence of doxorubicin. RNA was extracted 
from CALDOX cells grown in 0.4 μM doxorubicin or in the absence of doxorubicin for 5, 23, and 38 passages 
and from untreated CAL51 cells. qPCR measured p53CSV RNA levels that were normalised against expression 
levels of 18S and RPS6. Data represents a single experiment with 4 internal replicates (± SD).  
 
 
CALDOX cells grown in doxorubicin and CAL51 cells. cDNA was obtained through reverse 
transcription reactions. Quantitative PCR with SYBR Green was performed, and the 
expression of p53CSV was measured and normalised with two house-keeping genes, RPS6 
and 18S. CALDOX cells grown in doxorubicin had the highest levels of p53CSV RNA 
(RPS6: 2.88 fold; 18S: 3.81 fold), likely as p53CSV is also part of immediate response to 
genotoxic stress. However, p53CSV remained up-regulated in the absence of doxorubicin, 
compared to CAL51 cells, for up to 23 passages (p<0.05). At 38 passages, the data was 
inconclusive between two normalisers, but suggest that p53CSV levels are similar to those in 
CAL51 cells at this point. Collectively, the data suggests that p53CSV is part of both the p53 
response to doxorubicin and the long-term mechanism that CALDOX has developed against 
doxorubicin. 
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4.3 Expression of p53CSV in CALDOX and CAL51 in response to doxorubicin 
Previous work in our laboratory suggested that in CALDOX cells, the p53 cell repair 
and arrest pathways remained activated at high doses of doxorubicin (5-10 µM) while CAL51 
cells responded to the same doses with apoptosis. We aimed to confirm these results by 
ascertaining RNA levels of p53CSV, p21 and apoptotic gene p53AIP1 at different 
concentrations of doxorubicin using qPCR (Figure 4.4).  
CAL51 and CALDOX cells were grown in increasing concentrations of doxorubicin 
for 24 or 48 hours. RNA was extracted and cDNA was obtained through reverse transcription 
reactions. Quantitative PCR with SYBR Green was performed, and the expression of 
p53CSV, p21, and apoptotic p53AIP1 was measured and normalised with two "house-
keeping" genes, RPS6 and 60S acidic ribosomal protein P0 (RPLP0). In one case, two 
normalisers did not agree and a third normaliser was used as indicated (40S ribosomal protein 
S14 or RPS14). The expression of a gene at each concentration of doxorubicin was made 
relative to its expression in untreated (0 µM) cells (e.g. the expression of each gene in CAL51 
and CALDOX cells at 0 µM is set to 1). CAL51 gene expression was the combination of two 
separate experiments, where cells were grown in low doses (0, 0.1, 0.2, 0.3 µM) or high 
doses (0, 0.4, 1, 2, 5 µM) of doxorubicin but have been combined to observe trends. 
As p53AIP1 is part of the p53-dependent apoptotic pathway, it was not expressed in 
untreated CAL51 cells, or at low doses of doxorubicin (up to 0.2 μM). p53AIP1 expression 
experienced a 5000 fold increase at 0.3 µM doxorubucin. However, p53AIP1 was a difficult 
gene to measure, as in our cells, it was either highly upregulated, or not expressed at all. 
Thus, although we attempted to measure p53AIP1 with several different standards (CAL51 
untreated or CAL51 + 1 µM doxorubicin), we could not produce a standard curve that could 
accurately measure both high and low expression levels of p53AIP1. If untreated CAL51 
cells were used as a standard, cells expressing high levels of p53AIP1 fell outside the linear 
40 
 
 
 
 
 
 
 
0
1000
2000
3000
4000
5000
6000
RPS6 RPLP0
0
80
160
240
320
400
0
10
20
30
40
50
0
7
14
21
28
35
RPS6 RPLP0
0
3
6
9
12
15
0
3
6
9
12
15
0
0.8
1.6
2.4
3.2
4
RPS6 RPLP0
0
0.4
0.8
1.2
1.6
2
0
0.4
0.8
1.2
1.6
2
RPS6 RPS14
   
   
 
   
  p
53
C
S
V
 
 
 
   
   
p2
1 
 
 
 
   
   
   
   
  p
53
A
IP
1 
24 hours 24 hours 48 hours 
CAL51 CALDOX 
 0             0.04           0.1           0.2           0.3           0.4           1.0    2.0     5.0  
μM Doxorubicin 
 0         0.4        1.0        2.0        4.0 
μM Doxorubicin 
 
 0        0.4        1.0        2.0        4.0 
μM Doxorubicin 
41 
 
Figure 4.4 p53CSV and p21 are expressed in CALDOX cells at low and high concentrations of 
doxorubicin. CALDOX cells were grown in 0, 0.4, 1, 2. and 4 μM doxorubicin for 24 and 48 hours. CAL51 
cells were grown for 24 hours in 0, 0.04, 0.1, 0.2, and 0.3 μM doxorubicin and in separate experiment, 0, 0.4, 1, 
and 5 μM doxorubicin. RNA was extracted and expression levels of p21, p53AIP1, and p53CSV mRNA were 
quantified by qPCR and normalised with RPS6 and RPLP0. A third normaliser RPS14 was used in one case. 
Data represent single experiments with 3 internal replicates ± SD. Values are expressed relative to the mRNA 
levels obtained in cells growing in the absence of doxorubicin. 
 
range of the standard curve. Similarly, if treated CAL51 cells were used, samples with low 
levels of p53AIP1 fell outside the linear range. Thus, p53AIP1 levels should be looked at to 
observe a trend, rather than as an accurate measure of fold increase. The two CAL51 
experiments have been separated in Figure 4.5, to better observe the expression of p53AIP1 at 
both low and high doses: it was most up-regulated at 0.3-0.4 µM and its expression decreased 
in cells treated with higher cytotoxic concentrations (1-5 μM). 
 
 
 
 
Figure 4.5 Pro-apoptotic p53AIP1 is expressed at moderate doses of doxorubicin in 
CAL51 cells. Experiment as described in Figure 4.4: p53AIP1 mRNA levels were 
measured by qPCR in CAL51 cells were grown for 24 hours in 0, 0.04, 0.1, 0.2, and 0.3 
μM doxorubicin (A), and in a second experiment 0, 0.4, 1.0, 2.0, and 5.0 μM doxorubicin 
(B). p53AIP1 mRNA was up-regulated at 0.3 μM and slowly decreased as cells underwent 
apoptosis following 1-5 μM doxorubicin treatment. Data represent two single experiments 
with 3 internal replicates (± SD). Values are expressed relative to the mRNA levels of two 
normalisers: RPS6 and RPLP0. 
 
 
As expected, p21 was not expressed in untreated CAL51 cells. Starting at low 
concentrations of doxorubicin, p21 was up-regulated and its expression peaked at 0.3 µM 
before it was down-regulated at high concentrations of doxorubicin (0.4-5 µM), when cells, 
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through visual observation, had reached an apoptotic state. A similar pattern was observed for 
the expression of p53CSV was measured. p53CSV was up-regulated at 0.04 µM (2.0-2.2 fold) 
and its expression continued to increase up to 0.4 µM (2.8-3.2 fold) before decreasing as cells 
entered apoptosis (1-5 µM). 
However, in CALDOX cells, p53AIP1 was not highly expressed in cells treated with 
0 - 2 µM doxorubicin. It was only after 24 hours with 4 µM doxorubicin that CALDOX cells 
up-regulated p53AIP1. Like the 24 hour time point, p53AIP1 was not highly expressed 
between 0 - 1 µM doxorubicin at the 48 hour time point. However, it was up-regulated at 
slightly lower concentrations of doxorubicin than the 24 hour time point (7.7-8.8 fold at 2 
µM) likely due to the fact that cells had spent an additional 24 hours under stress in 
doxorubicin. 
p21 was up-regulated in CALDOX cells as doxorubicin concentrations increased at 
both 24 and 48 hour time points. p53CSV appeared to be induced by doxorubicin at 24 hours, 
although the data was less clear in this case. With normalization by RPS6, it experienced a 
1.6 fold increase at 0.4 µM, but it was not further induced at increasing concentrations of 
doxorubicin. In contrast, RPLP0 suggests that doxorubicin induced the expression of p53CSV 
from 1-2 µM, but not at concentrations between 0.4 and 4 µM. Previous experiments have 
shown that p53CSV is induced at 0.4 µM and it appears that RPS6 is the more reliable 
normaliser because it agrees with previous observations. Furthermore, at 48 hours, three 
normalisers were used, with RPLP0 being in disagreement with RPS6 and RPS14 (data not 
shown). Our protocol calls for the use of a third normaliser to decide between disputing data, 
and thus, we were able to conclude, using normalisers RPS6 and RPS14, that p53CSV was 
induced with increasing doses of doxorubicin. Unlike in CAL51 cells, p53CSV and p21 
expression levels did not decrease as doxorubicin doses increased, and the majority of 
CALDOX cells did not appear to be undergoing apoptosis.  
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In summary, the data suggests that the arrest and repair pathway (p53CSV and p21) 
remains activated at higher concentrations in CALDOX than in CAL51 cells. In the parental 
cells, p53CSV and p21 are up-regulated at low doses, but are not expressed at higher 
concentrations of doxorubicin. Furthermore, in CAL51 cells, apoptotic p53AIP1 is up-
regulated at lower doses of doxorubicin (0.3 µM) than in CALDOX (2-4 µM)—indicative of 
an earlier activation of cell death in the more sensitive parental cells. 
  
4.4 Stable overexpression of p53CSV in CAL51 
Transient knock-downs of p53CSV resensitised CALDOX cells to doxorubicin. 
Therefore, we postulated that stably over-expressing p53CSV in CAL51 would render cells 
more resistant to doxorubicin. CAL51 cells were transfected with linear vectors containing 
either p53CSV (513) or EGFP cDNA (D161) and a marker for selection with G418. Over-
expression of p53CSV was checked using qPCR using two normalisers: RPS6 and RPS14. 
We expected to see significant overexpression of p53CSV in transfected cells. However, 
CAL51 513a did not significantly up-regulate p53CSV compared to either control 
transfection (Figure 4.6; D161a and D161b; p>0.05). CAL51 513b showed slight, but 
significant up-regulation compared to both controls (1.49 fold, p<0.05), but an insignificant 
change compared to naive CAL51 cells. 
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Figure 4.6 p53CSV is not overexpressed in CAL51 cells transfected with p53CSV cDNA. 
CAL51 cells were stably transfected with linear vectors containing a selection marker and 
either p53CSV or control (EGFP) cDNA. p53CSV mRNA levels were measured by qPCR. 
p53CSV values are expressed relative to the mRNA levels of normalisers RPS6 and RPS14. 
Data represents a single experiment with 4 internal replicates ± SD. 
 
 
As 513b was thought to overexpress p53CSV at levels similar to CALDOX cells, we 
proceeded with the drug sensitivity assay. We plated cells containing p53CSV (513a-b), their 
controls (D161a-b), and non-transfected CAL51 in 96 well plates. After 24 hours, cells were 
resuspended in medium containing doxorubicin at ten different concentrations (serial 
dilutions from 0 - 2.5 µM). Cells were left to grow in the presence of doxorubicin for four 
days, before an SRB assay was performed to measure cell growth (Figure 4.7). For each cell 
line, the concentration of doxorubicin that inhibited growth by 50% compared to untreated 
cells was calculated (Table 4.1). We did not see a significant difference between CAL51 cells 
transfected with p53CSV and those transfected with EGFP.  
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Figure 4.7 Doxorubicin sensitivity is unchanged in CAL51 cells transfected with p53CSV 
cDNA. CAL51 cells were stably transfected with linear vectors containing a selection marker 
and either p53CSV or control (EGFP) cDNA. Cells were grown in the presence 0 – 2.5 μM 
doxorubicin for 4 days. Changes in cell numbers were determined by SRB growth assays. Data 
represents a single experiment with 6 internal replicates ± SD. Values are expressed relative to 
the absorbance obtained in cells growing in the absence of doxorubicin. 
 
 
Table 4.1 Half maximal inhibitory concentration (IC50) of doxorubicin 
 in CAL51 cells transfected with  p53CSV cDNA  
 
Cell Line IC50
 (μM) 
CAL51 0.030 
CAL51 + control vector (D161a) 0.027 
CAL51 + control vector (D161b) 0.025 
CAL51 + p53CSV (513a) 0.026 
CAL51 + p53CSV (513b) 0.029 
 
We sought to confirm poor p53CSV up-regulation through FACS analysis (Figure 
4.8). As cells transfected with p53CSV were expected to express p53CSV-EGFP fusion 
proteins, we expected to observe fluorescence these cells, as well as in the EGFP controls. 
Fluorescence was observed in a sub-population of each of the EGFP control cell lines D161a 
(23.5%, Figure 4.8d) and D161b (20.7%, Figure 4.8e). In p53CSV transfected cell lines, no 
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fluorescent shift or sub-population was observed (Figure 4.8b-c), and we concluded that 
p53CSV had been unsuccessfully transfected in CAL51. Thus, we concluded that the lack of 
change in drug sensitivity was the result of unsuccessful transfections, rather than the 
inability of p53CSV to mediate drug resistance.  
 
 
 
Figure 4.8 CAL51 cells transfected p53CSV-GFP cDNA do not fluoresce. Flow cytometry was 
utilized to observe fluorescence in CAL51 cells transfected with linear vectors that expressed either 
p53CSV-GFP or EGFP cDNA alone. Fluorescent cells (% in P3) were observed in the control vectors 
(B-C), but not in the p53CSV expressing cells (D-E), indicating that transfection had failed. 
 
4.5 Stable knock-down of p53CSV, p21 and p53 in CALDOX cells: first attempt 
To confirm that p53CSV mediated drug resistance in CALDOX, we stably transfected 
CALDOX cells with four different short hairpin RNAs (516-9) against p53CSV using a 
retrovirus. Down-regulation of p53CSV was confirmed with qPCR using two normalisers 
0.1% 23.5% 
20.7% 
1.6% 0.4% 
    A. CAL51         B. CAL51 + EGFP (D161a)        C. CAL51 + EGFP(D161b 
    D. CALDOX + p53CSV (513a)          E. CALDOX + p53CSV (513b) 
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(RPS6 and RPLP0; Figure 4.9). A decrease in p53CSV RNA levels was observed in all four 
cell lines (516-519) compared to a cell line transfected with a scrambled short hair pin control 
(515). CALDOX cell lines 516 (RPS6 61.5% p=0.0015; RPS14 76.4% p=0.0036) and 517 
(RPS6 73.0% p<0.0001; RPS14 78.5% p=0.0017) were selected for drug assays, as they 
experienced the greatest down-regulation of p53CSV. 
 
Figure 4.9 p53CSV is successfully down-regulated in CALDOX cells transfected with 
shRNA that targets p53CSV. CALDOX cells were stably transfected with short hairpin RNAs 
that targeted p53CSV (516-519) or scrambled control RNA. p53CSV mRNA levels were 
measured by qPCR. p53CSV values are expressed relative to the mRNA levels of normalisers 
RPS6 and RPLP0. Data represents a single experiment with 3 internal replicates ± SD. This 
experiment was repeated at a later passage with the same result (data not shown). 
 
 
Changes in sensitivity to doxorubicin following p53CSV knock-down were measured 
by SRB growth assays. Cells were plated overnight before resuspension in doxorubicin (0-2.5 
µM) for four days. The absorbance at each concentration, representative of cell number and 
growth, was plotted as a percentage of the untreated control (Figure 4.10). The half-maximal 
inhibitory concentration (IC50) were calculated (Table 4.2) for CALDOX (no transfection), 
CALDOX 515 (sh EGFP), and the two CALDOX p53CSV knock-downs (516-7). CALDOX 
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cells transfected with sh p53CSV were slightly more sensitive to doxorubicin than the 
negative control, but were similar in sensitivity to non-transfected CALDOX. Thus, these 
results are unlikely to be representative of a change in drug sensitivity. 
 
 
Figure 4.10 Doxorubicin sensitivity is unchanged in CALDOX cells that stably down-
regulate p53CSV. CALDOX cells were stably transfected with short hairpin RNA that 
targeted either p53CSV (516-7) or scrambled control RNA. Cells were grown in the presence  0 
– 5 μM doxorubicin for 4 days. Changes in cell numbers were determined by SRB growth 
assays. Data represents a single experiment with 6 internal replicates ± SD. Values are 
expressed relative to the absorbance obtained in cells growing in the absence of doxorubicin. 
 
 
 
Table 4.2 Half maximal inhibitory concentration (IC50) of doxorubicin 
 in CALDOX cells transfected with short hairpin mRNAs that down-regulate p53CSV  
 
Cell Line IC50
 (μM) 
CALDOX 0.83 
CALDOX + control vector (515) 0.93 
CALDOX + sh p53CSV (516) 0.80 
CALDOX + sh p53CSV (517) 0.79 
 
 Array data indicated that p21 was up-regulated in CALDOX cells, as were other p53-
inducible genes. We postulated that the p53 pathway plays a role in drug resistance in 
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CALDOX and that knocking-down the expression of p53 and its targets could mediate drug 
resistance in CALDOX cells. CALDOX cells were stably transfected with short hairpin 
RNAs against p53 or p21 using retroviral transfection. Quantitative PCR (using RPS6 and 
RPS14 as normalisers) confirmed that p53 was knocked-down in CALDOX cells (Figure 
4.11a). CALDOX cells transfected with shRNA against p21 did not show decreased 
expression of p21 (RPS14 12.6% p=0.1992; RPS6 16.8% p=.1397; Figure 4.11b), and the 
transfection was assumed to be a failure. Interestingly, the p53 stable knock-down showed 
some, but incomplete, down-regulation of p53CSV (RPS14 50.3% p=0.0095; RPS6 33% 
p=0.0109; Figure 4.11c). As expected, p21 expression was significantly decreased in the p53 
stable knock-down (RPS14 84.6% p=0.0008; RPS6 79.2 p=0.0005; Figure 4.11b). 
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Figure 4.11 p53 but not p21 is successfully down-regulated in CALDOX cells transfected 
with shRNA that targets p53 or p21. CALDOX cells were stably transfected with short 
hairpin RNAs that targeted p53, p21, or scrambled control RNA. p53 (A), p21(B), p53CSV (C) 
mRNA levels were measured by qPCR. A. p53 was successfully down-regulated in CALDOX 
transfected with sh p53. B. p21 was down-regulated in CALDOX cells transfected with sh p53 
but not in cells transfected with sh p21. C. p53CSV was also down-regulated in cells 
transfected with sh p53.Values are expressed relative to the mRNA levels of normalisers RPS6 
and RPS14. Data represents a single experiment with 3 internal replicates ± SD. 
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 Changes in doxorubicin sensitivity in CALDOX cells transfected with sh p53 were 
measured by an SRB assay as previously described (Figure 4.12). Growth was inhibited by 
50% at 6.5 µM doxorubicin in CALDOX sh p53 and 5.6 µM (Table 4.3) in the negative 
scrambled control—suggesting that CALDOX sh p53 cells were 1.16 fold more resistant to 
doxorubicin. However, there was significant overlap in error, as observed in Figure 4.12, and 
we cannot conclude a significant change in drug sensitivity in CALDOX as a result of p53 
knock-down. 
 
Figure 4.12 Doxorubicin sensitivity is unchanged in CALDOX cells that stably knock-
down p53. CALDOX cells were stably transfected with short hairpin RNA that targeted either 
p53 or control scrambled RNA. Cells were grown in the presence 0 – 5 μM doxorubicin for 4 
days. Changes in cell numbers were determined by SRB growth assays. Data represents a 
single experiment with 6 internal replicates ± SD. Percentages are relative to the absorbance 
obtained in cells growing in the absence of doxorubicin. 
 
 
Table 4.3 Half maximal inhibitory concentration (IC50) of doxorubicin 
 in CALDOX cells transfected with short hairpin mRNAs that down-regulate p53  
 
Cell Line IC50
 (μM) 
CALDOX + control vector (515) 5.64 
CALDOX + sh p53 6.51 
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4.6 Stable knock-down of p53CSV, p21 and p53 in CALDOX: second attempt 
As previous p53CSV and p53 stable knock-downs in CALDOX cells did change not 
drug sensitivity and because the p21 knock-down did not depress p21 levels, we chose to 
repeat the short hair pin transfections for p21, p53, and p53CSV. Retroviral transfections were 
performed as described above by Dr. S. Raguz. Quantitative PCR was used to confirm p21, 
p53CSV, and p53 expression with two house-keeping genes (RPS6, RPS14).  
In CALDOX cells transfected with sh p53, p53 was successfully down-regulated 
(RPS6 92.4%, p<0.001; RPS14 93.0%, p<0.001; Figure 4.13a), as were p21 (RPS6 82.2% 
p=0.0001; RPS14 83.5% p=0.0001; Figure 4.13b), and p53CSV (RPS6 15.4%, p=0.051; 
RPS14 21.6%, p=0.027; Figure 4.13c). In CALDOX cells transfected with shRNA against 
p21, p21 was successfully down-regulated (RPS6 51.7% p=0.0001; RPS14 59.6% p=0.0001; 
Figure 4.13b). In CALDOX cells transfected with sh p53CSV, p53CSV was knocked down 
(Figure 4.13c) in both 516 (RPS6 81.1% p<0.0001; RPS14 76.9% p<0.001) and 517 (RPS6 
81.1% p<0.0001; RPS14 84.1% p<0.001).  
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Figure 4.13 p53, p21, and p53CSV (516-7) are successfully down-regulated in CALDOX cells 
transfected with shRNA against p53, p21, or p53CSV (second transfection attempt). 
CALDOX cells were stably transfected with short hairpin RNAs that targeted p53, p21, or 
scrambled control RNA. p53 (A), p21(B), p53CSV (C) mRNA levels were measured by qPCR. A. 
p53 was successfully down-regulated in CALDOX transfected with sh p53. B. p21 was down-
regulated in CALDOX cells transfected with sh p53 and sh p21. C. p53CSV was down-regulated 
in cells transfected with sh p53 or sh p53CSV.Values are calculated against the mRNA levels of 
normalisers RPS6 and RPS14. Data represents a single experiment with 3 internal replicates ± SD.  
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SRB drug assays were used to determine differences in doxorubicin sensitivity 
between stable cell lines. Two separate drug assays were performed to keep the experiment 
manageable. In the first, CALDOX shRNA against p21, p53CSV (517), and p53 were 
compared to CALDOX cells transfected with negative controls (empty vector 514 and 
scrambled sh 515). The percent growths compared to untreated controls were plotted for each 
cell line, and significant overlap can be observed (Figure 4.14). Furthermore, calculated IC50s 
did not significantly differ between cell lines (Table 4.4), suggesting that stably knocking 
down p21, p53, or p53CSV alone does not mediate drug resistance in CALDOX cells. 
 
Figure 4.14 Doxorubicin sensitivity is unchanged in CALDOX cells that stably knock-
down p53CSV (517), p53, or p21 (second transfection attempt). CALDOX cells were stably 
transfected with short hairpin RNA that targeted p53CSV, p53, p21, or control (scrambled or 
EGFP) RNA. Cells were grown in the presence 0 – 5 μM doxorubicin for 4 days. Changes in 
cell numbers were determined by SRB growth assays. Data represents a single experiment with 
6 internal replicates ± SD. Values are expressed relative to the absorbance obtained in cells 
growing in the absence of doxorubicin. 
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Table 4.4 Half maximal inhibitory concentration (IC50) of doxorubicin in CALDOX cells transfected with 
short hairpin mRNAs that down-regulate p53CSV (517), p21, or p53 (second attempt) 
 
Cell Line IC50
 (μM) 
CALDOX + control vector (514) 0.14 
CALDOX + control vector (515) 0.18 
CALDOX + sh p21 0.16 
CALDOX + sh p53 0.19 
CALDOX + sh p53CSV (517) 0.18 
 
A second SRB assay was performed, to measure the differences in doxorubicin 
sensitivity between CALDOX transfected with sh p53CSV (516) or sh p53 and negative sh 
controls. As before, the empty vector control appeared to be more sensitive than the other 
scrambled control and the experimental knock-downs. However, the scrambled control vector 
is more appropriate to use as a negative control, as it contains scrambled shRNA that can 
account for cellular changes due to sh transfections. Again, we did not observe significant 
changes between CALDOX sh p53 or sh p53CSV (516) and the negative scrambled control 
(Figure 4.15 and Table 4.5). 
 
Figure 4.15 Doxorubicin sensitivity is unchanged in CALDOX cells that stably knock-
down p53CSV (516) or p53 (second transfection attempt). CALDOX cells were stably 
transfected with short hairpin RNA that targeted either p53CSV or control (EGFP) RNA. Cells 
were grown in the presence 0 – 5 μM doxorubicin for 4 days. Changes in cell numbers were 
determined by SRB growth assays. Data represents a single experiment with 6 internal 
replicates ± SD. Values are expressed relative to the absorbance obtained in cells growing in 
the absence of doxorubicin. 
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Table 4.5 Half maximal inhibitory concentration (IC50) of doxorubicin in CALDOX  
cells transfected with short hairpin mRNAs that down-regulate p53CSV (516) or p53 (second attempt) 
 
Cell Line IC50
 (μM) 
Caldox + empty vector (514) 0.19 
Caldox + control vector (515) 0.23 
Caldox + sh p53 0.23 
Caldox + sh p53CSVa (516) 0.25 
 
A final SRB assay was performed to confirm the role of p53 in drug sensitivity, as 
previous experiments yielded disparate results (Figure 4.16). Interestingly, CALDOX cells in 
which p53 was down regulated were observed to be more sensitive to doxorubicin compared 
to the scrambled control in this case (0.63 fold resistant; Table 4.6). However, the observed 
error makes this result non-significant. In total, the role for p53 in CALDOX was 
inconclusive, as in three different experiments, shRNA againsts p53 mRNA rendered cells 
more sensitive, indifferent, or more resistant to doxorubicin. 
 
Figure 4.16 Doxorubicin sensitivity is not significantly different in CALDOX cells that 
stably knock-down p53 (second transfection attempt). CALDOX cells were stably 
transfected with short hairpin RNA that targeted either p53 or scrambled control RNA. Cells 
were grown in the presence 0 – 5 μM doxorubicin for 4 days. Changes in cell numbers were 
determined by SRB growth assays. Data represents a single experiment with 6 internal 
replicates ± SD. Values are expressed relative to the absorbance obtained in cells growing in 
the absence of doxorubicin. 
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Table 4.6 Half maximal inhibitory concentration (IC50) of doxorubicin in CALDOX 
 cells transfected with short hairpin mRNAs that down-regulate p53 (second attempt) 
 
Cell Line IC50
 (μM) 
CALDOX + control vector (515) 0.61 
CALDOX + sh p53 0.39 
 
4.7 p53CSV expression in normal tissues 
Our data indicated that p53CSV is not completely down-regulated in the absence of 
p53. Thus, it is possible that it has a role outside of the p53 response to cellular stress, and 
that it could be expressed in normal, non-tumourigenic tissues. We measured the gene 
expression of p53CSV in healthy human tissues using an RNA panel (Invitrogen). Following 
reverse transcription, qPCR was performed with four normaliser genes: 18S, RPLP0, RPS6 
and RPS14. Normalisers RPS6 and RPS14 showed the most consistent pattern of expression 
and were considered reproducible. 
p53CSV was widely expressed in normal human tissues (Figure 4.17). However, most 
tissues did not express p53CSV to the levels that it was expressed CAL51 and CALDOX 
cells. p53CSV was expressed at levels similar to CAL51 in the brain (fetal, whole, and 
cerebellum), placenta, skeletal muscle, and testis; however, p53CSV was most highly 
expressed in CALDOX cells by at least 1.5 times more (mean: 4.3 fold, RPS6) than normal 
tissues. p53CSV was least expressed in the heart, kidneys, and bone marrow. 
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Figure 4.17 p53CSV is widely expressed in normal tissue. cDNA was obtained by reverse transcription from an RNA panel of healthy human tissues (Invitrogen). CAL51 and 
CALDOX RNA were included for comparison. Quantitative PCR was performed with four normalisers (18S, RPLP0, RPS6, RPS14) and the two that agreed most were considered 
reproducible. Data represents a single experiment with 3 internal replicates ± SD. Values are expressed relative to the mRNA levels of normalisers RPS6 and RPS14. 
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4.8 p53CSV expression in estrogen-independent ER+ MLET5 and parental MCF7 cells 
We next investigated the role of p53CSV in survival following DNA cellular stress in 
a second breast cancer cell line provided by Drs Ali Simak and Laki Bulawela. Their array 
data suggested that in their estrogen independent cells, ER+ MLET5, p53CSV was 
approximately 8 times up-regulated compared to the parental estrogen dependent MCF7 cell 
line. In both MCF7 and their MLET5 cells, the presence of estrogen or its absence did not 
change the expression of p53CSV. We aimed to confirm their data with qPCR. MLET5 and 
MCF7 cells were grown in medium with or without estrogen for 3 days. cDNA was obtained 
following RNA extractions and reverse transcription reactions. Quantitative PCR was 
performed with two normaliser genes (RPS6 and RPS14), and p53CSV and p21 expression 
levels were measured. 
 
 
 
Figure 4.18 p53CSV is up-regulated and can be further induced by estrogen 
withdrawal in MLET5 cells. In MCF7 cells, p53CSV expression levels were unaffected 
by estrogen withdrawal. MLET5 and MCF7 cells were grown in the presence or absence 
of estrogen for 3 days. p53CSV mRNA levels were measured by qPCR. p53CSV values 
are expressed relative to the mRNA levels of normalisers RPS6 and RPLP0. Data 
represents a single experiment with 3 internal replicates ± SD. MLET5 and parental 
MCF7 cells were kindly provided by Drs Laki Buluwela and Simak Ali.  
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In concordance with array data, p53CSV (Figure 4.18) was up-regulated in MLET5 
cells (RPS6 1.41 fold, p=0.015; RPS14 1.43 fold, p=0.075). Yet, the absence of estrogen 
strongly induced p53CSV expression in MLET5 (RPS6 1.82 fold, p=0.0001; RPS14 1.47 
fold, p=0.005), but not in MCF7 (RPS6 1.00 fold, p=0.99; RPS14 0.87 fold, p=0.7). We 
expected that p53CSV levels would parallel p21 expression, as both are part of the p53-
dependent arrest and repair pathway. However, although p21 (Figure 4.19) was up-regulated 
in MLET5 cells (RPS6 1.94 fold, p=0.003; RPS14 1.96 fold, p=0.04), it was not strongly 
inducible in the absence of estrogen (i.e. cellular stress; RPS6 1.10 old, p=0.15; RPS14 0.89 
fold, p=0.4). In MCF7 cells, p21 was expressed at low levels in the presence of estrogen, but 
when cells were starved from estrogen, p21 was induced and up-regulated (RPS6 2.51 fold, 
p=0.001; RPS14 2.15 fold, p=0.05). 
 
 
Figure 4.19 p21 expression is up-regulated but unaffected by estrogen withdrawal 
in MLET5 cells. In MCF7 cells, p53CSV was significantly induced by estrogen 
withdrawal. MLET5 and MCF7 cells were grown in the presence or absence of 
estrogen for 3 days. p21 mRNA levels were measured by qPCR. p21 values are 
expressed relative to the mRNA levels of normalisers RPS6 and RPLP0. Data 
represents a single experiment with 3 internal replicates ± SD. MLET5 and parental 
MCF7 cells were kindly provided by Drs Laki Buluwela and Simak Ali. 
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4.9 Drug resistance in CALDOX cells 
Cells that become resistant to one type of chemotherapy often become resistant to 
other chemotherapeutic regimens as well (i.e. multi-drug resistant). We compared the 
sensitivity of our CALDOX cell line to parental CAL51 to multiple chemotherapy drugs. 
CAL51 and CALDOX cells were plated in 96-well plates at two separate concentrations and 
were left in drug-free medium for 24 hours by Dr. Raguz. Doxorubicin, Etoposide, Cisplatin, 
Taxol, Hydrogen Peroxide, Camptothecin, or 5-Fluorouracil was added the next day by serial 
dilution at concentrations as established by previous literature (Table 4.7). After 3 doubling 
times, an SRB assay was performed to measure cell growth. The percent growth compared to 
the untreated control (100%) at each concentration was determined and plotted with the help 
of Dr. Yagüe (data not shown). The IC50 was determined by linear regression from the 
steepest part of the plotted slope. Fold regression for each drug was calculated by dividing the 
CALDOX IC50 by the CAL51 IC50. Interestingly, CALDOX cells were most resistant to 
Etoposide (150 fold) compared to CAL51. CALDOX cells were, unsurprisingly, more 
resistant to doxorubicin than CAL51 (45 fold). CALDOX cells were weakly resistant to 
Hydrogen peroxide (1.41 fold), Cisplatin (1.47 fold) and Taxol (2.62 fold) compared to 
CAL51. CALDOX cells were neither resistant nor more sensitive to Camptothecin (1.25 
fold). However, these cells were more sensitive to 5-fluorouracil than parental CAL51 (0.47 
fold less resistant). 
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Table 4.7 Comparing drug sensitivity of CALDOX and CAL51* 
 
Drug (cell line) Drug Concentration 
Range (μM) 
LD50 (μM) Fold Resistance 
Etoposide   150 
CALDOX 0 – 100 >100  
CAL51 0 – 10  0.65  
Doxorubicin   45.0 
CALDOX 0 – 20  0.675  
CAL51 0 – 5  0.015  
Cisplatin   1.47 
CALDOX 0 – 100  30.50  
CAL51 0 – 100  20.75  
Taxol   2.62 
CALDOX 0 – 100 9.25  
CAL51 0 – 100 3.53  
5-Fluorouracil   0.47 
CALDOX 0 – 1150 12.0  
CAL51 0 – 1150 25.5  
Camptothecin   1.25 
CALDOX 0 – 1  0.088  
CAL51 0 – 1  0.070  
Hydrogen Peroxide    1.41 
CALDOX 0 – 8.8  0.56  
CAL51 0 – 8.8  0.40  
*Drug assays and data analyses were performed with help from Dr. Sabeena Rashied, Dr. Selina Raguz, and Dr. Ernesto Yagüe. 
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5. Discussion  
5. 1 The role of p53CSV and the p53 pathway in CALDOX cells 
 p53 is a transcription factor that is stabilized and activated in cells experiencing 
genotoxic stress. At reparable levels of DNA damage, p53 activates genes that induce cell 
arrest and DNA repair. At high and irreversible levels of genotoxic stress, p53 instead 
promotes the transcription of genes which lead to programmed cell death (apoptosis).40 In 
tumourigenesis, p53 has been co-opted as a tumour suppressor, as both its p21 repair and 
apoptotic pathways prevent the proliferation of uncontrolled, oncogenic cells.10 However, 
p53 may have a role in chemotherapy resistance. Inhibition of its apoptotic pathway and up-
regulation of its arrest and repair pathway have been implicated in multidrug resistance.72 
This is particularly important in triple-negative breast cancer patients who do not have 
alternative treatment options outside of chemotherapy. p53 is commonly mutated in 
cancers.25-26 New therapies that reactivate p53 are in development, and thus it is especially 
crucial we understand the implications that p53 may have in chemotherapy response.73  
 Our laboratory has generated a triple-negative doxorubicin resistant breast cancer cell 
line, CALDOX, to better understand the biological mechanisms of drug resistance in breast 
cancer. An RNA array revealed an up-regulation of p21, and also a novel gene to mammalian 
drug resistance, p53CSV, in CALDOX cells (compared to parental CAL51 cells). As CAL51 
cells were not treated with doxorubicin, CALDOX cells were also grown in the absence of 
doxorubicin prior to the array, in order to separate genes that were differentially expressed as 
part of the drug response from those that mediated drug resistance. p53CSV was first 
described in 2005 as a p53-inducible gene and it was suggested that it plays a role in the 
arrest and repair pathway by inhibiting the cleavage of pro-caspase-9 and the activation of 
apoptosis.57 
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 Quantitative PCR confirmed the array results. p53CSV was overexpressed in 
CALDOX cells treated with doxorubicin (compared to untreated CAL51 cells). A second 
experiment was performed to separate whether p53CSV was up-regulated as part of the 
molecular changes that accompanied MDR or as part of the cellular reponse to genotoxic 
stress, and showed that p53CSV was up-regulated in CALDOX cells that were grown for up 
to twenty three passages in the absence of doxorubicin. In addition, p53CSV was further 
induced in CALDOX cells that were grown in 0.4 μM doxorubicin.  
Analysis of the activation of the p53 pathway in CAL51 and CALDOX cells at 
different concentrations of doxorubicin (representative of differing levels of genotoxic stress) 
was conducted. p21 and p53CSV were activated at low levels of DNA damage in CAL51 
cells (0.01-0.4 μM doxorubicin). At moderate to high levels of DNA damage, p21 and 
p53CSV expression levels decreased as cells became increasingly sick and apoptotic. As p21 
and p53CSV expression levels decreased, apoptotic p53AIP1 was induced at 0.3 μM of 
doxorubicin. At the highest levels of DNA damage, RNA expression decreased for all 
measurable genes—which was to be expected, as cells undergoing apoptotsis experience 
programmed break-down of RNA. This pattern of arrest and repair, as evidenced by p21 and 
anti-apoptotic p53CSV at low doses of doxorubicin, but apoptosis at high doses was strikingly 
different in CALDOX cells. CALDOX cells did not undergo apoptotsis, even at high levels 
of genotoxic stress. Instead, p53CSV and p21 were induced at low doses of doxorubicin and 
remained up-regulated in concentrations as high as 10 μM. p53AIP1 was only induced at the 
highest concentration (10 μM). This shift in p53 response appeared to protect CALDOX cells 
from doxorubicin induced death. p53CSV correlated well with the p21 response, providing 
further support for its role in p53-induced cell survival.  
Thus, we can infer that p53CSV is part of the immediate response to cellular stress in 
CALDOX cells, that it is up-regulated in CALDOX cells as part of the p53 pathway and that 
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its continued activity at high doses of doxorubicin, play a role in resistance. However, as we 
did not measure p21 and p53AIP1 levels in CALDOX cells deprived of doxorubicin for 
multiple passages, we cannot firmly conclude that the long-term up-regulation of p53CSV in 
CALDOX is representative of a similar widespread change in the p53 pathway. However, 
array data suggests that p21 is also up-regulated in CALDOX, independently of doxorubicin 
(data not shown); and thus p53CSV is likely part of a widespread p53 dependent mechanism 
that promotes MDR in CALDOX cells. 
Stable knock-downs of p21, p53, and p53CSV were generated in order to directly 
assess the role of the p53 pathway in drug-resistant CALDOX cells. Our transient knock-
down of p53CSV rendered CALDOX cells more sensitive to doxorubicin, and we expected 
our p53CSV stable knock-downs in CALDOX cells would experience a similar effect. 
However, repeated p53CSV knock-downs, confirmed by qPCR, did not show a change in 
drug sensitivity. Transient knock-downs were not confirmed with qPCR, and it is possible 
that the change in drug sensitivity was due to a separate effect; however, RNAi is normally 
highly successful in completely knocking-down the gene. If we make this assumption, it is 
possible that complete knock-down is required to observe an effect, as stable knock-downs 
typically (and in our case) only down-regulate gene expression by 60-70%. As multi-drug 
resistance is normally the result of a multitude of genetic, transcriptional, and translational 
changes, partial down-regulation of p53CSV was not enough to resensitise cells to genotoxic 
stress. Until we repeat transient experiments and verify p53CSV knock-down, we were unable 
to determine whether p53CSV alone can mediate drug resistance in CALDOX cells. 
However, stable knock-downs suggest that p53CSV is part of a larger picture in mediating 
MDR in CALDOX cells. We postulated that this picture included other p53-inducible genes, 
specifically the up-regulation of antiapoptotic and DNA repair genes, and the down-
regulation of pro-apoptotic genes, such as p53AIP1. To this effect, we attempted to stably 
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knock-down p21 in CALDOX. However, our transfections were largely unsuccessful, with 
complete failure in one case and only 50% reduction in another. In the latter case, we did not 
see an effect on drug sensitivity. Like with p53CSV, this could be because it does not have a 
significant effect until it is completely knocked down. Even more likely, multiple genes 
would need to be successfully knocked down to observe an effect on drug resistance (such as 
p21 and p53CSV together). Unfortunately, over-expression of p53CSV in CAL51 cells failed, 
and could not be used to draw further conclusions about the role of p53CSV in doxorubicin 
resistance. 
Finally, we were able to successfully down-regulate p53 in CALDOX cells. However, 
the resulting change in drug sensitivity was inconsistent, and in most cases, non-significant. 
This was not surprising, as p53 is associated with increases in drug sensitivity in some cases, 
but also in decreases in other studies.74-75 Although the expression of wildtype p53 is 
popularly associated with chemosensitvity, a single point mutation on wildtype p53 rendered 
cells more sensitive to docetaxel because the mutant p53 could more efficiently induce 
apoptotic genes.72 These varied responses are likely due to the disparate effects that the two 
p53 response pathways have in chemotherapy.10 Ultimately, the choice to undergo arrest and 
repair or programmed death will depend upon the balance of pro-apoptotic versus anti-
apoptotic proteins in the cell.76 In CALDOX cells, we can infer that the inability to trigger 
p53-induced repair (thus sensitising cells to doxorubicin) would be negated by the equal 
inability to trigger p53-dependent apoptosis. This especially highlights the importance of 
targeting or expressing particular pathways in p53, rather than the transcription factor as a 
whole. 
In short, our data supports previous studies that implicate p53CSV in early response 
to manageable levels of genotoxic stress as part of the p53-dependent pathway. In CALDOX 
cells, p53CSV likely plays a role in drug-resistance and drug-response as part of the p53 cell 
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repair and arrest pathway. However, p53CSV alone is not enough to mediate drug resistance 
in our triple-negative breast cancer cell line.  
5.2 Role of p53CSV in MLET5 cells 
The deletion of p53CSV ortholog MDM35 in yeast increased sensitivity to 
doxorubicin and was part of a larger survey for genes that mediated drug resistance by 
improving G1 and early S phase repair and checkpoint mechanisms.
65 Similarly, in our 
CALDOX cells, p53CSV has a potential role in the p53-dependent cell arrest and repair 
pathway by inhibiting apoptosis. As this pathway is not drug specific, as long as the chemo or 
hormone regimen induces p53 response pathways, we obtained array data for p53CSV in 
MLET5 cells. MLET5 cells are an ER+ MCF7 breast cancer cell line that can grow 
independently of estrogen, and are less sensitive to tamoxifen and etoposide.  
Generated by Dr. Simak Ali and Dr. Laki Buluwela, MLET5 cells survive low 
estrogen conditions through up-regulation of anti-apoptotic Bcl-2 family members and down-
regulation of pro-apoptotic Bcl-2 family members.77 The Bcl-2 family plays a role in the 
stabilization of the mitochondrial membrane, and the balance of pro-apoptotic to anti-
apoptotic members determines cell fate. Furthermore, p53 plays a role in Bcl-2 (the anti-
apoptotic founder of this family) inactivation both by direct binding and transcription of pro-
apoptotic Bcl-2 family members.78 Thus, the p53 pathway could play a direct role in the 
survival of MLET5 in low estrogen conditions. Their array data indicated that p53CSV was 
up-regulated by a factor of eight in MLET5 cells. The presence of estrogen did not affect the 
expression of p53CSV in either MCF7 or MLET5. We postulated that p53CSV played a role 
in preventing apoptosis in MLET5 cells, perhaps independently of p53—as stress did not 
induce the expression of p53CSV in either cell line.  
Quantitative PCR was used to confirm the array data. In accord with the array, we 
found that p53CSV was up-regulated in MLET5 cells compared to MCF7 cells. Furthermore, 
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the presence or absence of estrogen did not affect the expression of p53CSV in MCF7 cells. 
However, our data disagreed with the array as we observed a significant induction of p53CSV 
during estrogen withdrawal in MLET5 cells. This was different from the expression of p21 in 
MLET5 and MCF7 cell lines. Although p21 was also significantly up-regulated in MLET5 
cells, it was not further induced during estrogen withdrawal. Meanwhile, MCF7 cells that 
were grown in the absence of estrogen significantly induced the expression of p21. From this 
data, we can infer that the p53 anti-apoptotic pathway is up-regulated in MLET5 cells. 
However, p53CSV could be induced separately from the p53 arrest and repair pathway in low 
estrogen conditions in MLET5 cells. Knock-down experiments of p53 and p53CSV in 
MLET5 cells would help to elucidate the importance of p53 and p53CSV in MLET5 cells 
under low and normal estrogen conditions. Nevertheless, it is clear that p53CSV is a potential 
therapeutic target for increasing sensitivity to a number of different therapies in varying types 
of breast cancer. 
5.3 p53-independent role of p53CSV 
 In their original paper, Park and Nakamura claimed that p53CSV was completely 
dependent upon activation by p53.57 When in fact, their data suggest that p53CSV is 
expressed at low levels independently of p53 activation and genotoxic stress; and that p53 
knock-downs do not completely eradicate the expression of p53CSV. p53CSV would not be 
the only p53-induced gene to have a function separate from the p53 pathway. For example, 
p21 is known to be transcribed and function separately from p53 and our p53 knock-downs 
did not completely abrogate p21 expression.79 Similarly, we found that p53 stable knock-
downs (93%), confirmed by qPCR, did not substantially down-regulate the expression of 
p53CSV (20%). However, in CALDOX cells that have been selected by their ability to escape 
apoptosis, p53CSV could be partially up-regulated independently of p53.  
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We found that, p53CSV is expressed throughout normal healthy tissues, albeit at 
lower levels than in CALDOX cells. This suggests that its p53-independent transcription is 
not limited to CALDOX. A previous study has implicated the necessity of p53CSV in the 
development of the larval kidney in Xenopus (African frog).80 Its high degree of 
conservation, not only in mammals but also in lower organisms such as yeast, could indicate 
that its ability to inhibit apoptosis and allow G1 arrest and DNA repair may also be important 
for the regulation of proliferating cells during development. Our lab is currently cloning the 
promoter region of p53CSV with the aim to elucidate the transcriptional regulation of 
p53CSV. 
5.4 Multidrug resistance in CALDOX cells 
 Multidrug resistance is defined by the ability of cells to become less responsive to 
more than one type of therapy, including ones that they may not have been exposed to 
previously. SRB assays were performed to measure the resistance of CALDOX cells to a 
wide array of chemotherapeutic drugs. Interestingly, CALDOX cells were most resistant to 
etoposide (150 fold) and doxorubicin (45 fold) compared to CAL51 cells. Importantly, these 
two drugs assert their genotoxic effect through inhibition of topoisomerase II, which is 
important for unwinding DNA during replication in the S phase.81 The other drugs do not 
induce apoptosis and cellular stress in this way, and camptothecin inhibits topoisomerase I. 
Previous research has indicated that topoisomerase II alterations or changes in its expression 
play a role in MDR.82 However, topoisomerase II was not differentially expressed in 
CALDOX cells, but it is possible that single point mutations (undetectable in our comparative 
genomic hybridazation assays) may alter the ability of these drugs to interact and inhibit 
topoisomerase II. Current work in our lab is underway to sequence topoisomerase II for 
mutations in CALDOX cells.  
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Finally, CALDOX cells were not, on the whole, more resistant to Pgp substrates 
(doxorubicin, taxol, etoposide, camptothecin) than drugs that are not effluxed by ABC 
transporters (hydrogen peroxide, cisplatin, 5-fluoruracil)—supporting our preliminary data 
that ruled out drug efflux as a significant mediator of MDR in CALDOX cells. 
5.5 Conclusions 
 The up-regulation of the p53 arrest and repair pathway is likely one player in the 
multifactorial drug-resistance of CALDOX cells. p53CSV likely plays a p53-dependent role 
in CALDOX cells as an inhibitor of apoptosis. However, some of its effects may be 
independent of p53. Nevertheless, p53CSV as well as p21 and other DNA repair proteins are 
an important reminder of the possible pro-tumourigenic and pro-resistant role of p53 in 
cancer. It will be important in future therapies when considering p53 or its two disparate 
downstream pathways as potential therapeutic targets. Furthermore, p53CSV is well 
conserved in mammals, and could play a role in development independently of p53. 
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6. Appendix 
 
Table 6.1 Full length amino acid sequences of P53CSV in select vertebrates*  
Protein Acc. Gene Organism Full Amino Acid Sequence 
NP_057483.1 TRIAP1 Homo sapiens (Human) MNSVGEACTDMKREYDQCFNRWFAEKFLKGDSSGDPCTDLFKRYQQCVQKAIKEKEIPIEGLEFMGHGKEKPENSS 
XP_001160868.1 TRIAP1 Pan troglodytes (Chimpanzee) 
MNSVGEACTDMKREYDQCFNRWFAEKFLKGDSSGDPCTDLF
KRYQQCVQKAIKEKEIPIEGLEFMGHGKEKPENSS 
XP_546335.2 TRIAP1 Canis lupus familiaris (Dog) MNSVGEACTDMKREYDQCFNRWFAEKFLKGDGSGDPCTDLFKRYQQCVQKAIKEKEIPIEGLEFMGHGKEKPESSS 
NP_001073244.1 TRIAP1 Bos taurus (Cow) MNSVGEACTDMKREYDQCFNRWFAEKFLKGDGSGDPCTDLFKRYQQCVQKAIKEKEIPIEGLEFMGHGKEKPESSS 
NP_081209.1 TRIAP1 Mus musculus (Mouse) MNSVGEACTDMKREYDQCFNRWFAEKFLKGDGSGDPCTDLFKRYQQCVQKAIKEKEIPIEGLEFMGHGKEKPENSS 
XP_001077518.1 TRIAP1 Rattus norvegicus (Rat) MNSVGEACTDMKREYDQCFNRWFAEKFLKGDGSGDPCTDLFKRYQQCVQKAIKEKEIPIEGLEFMGHGKEKPENSS 
XP_429464.2 TRIAP1 Gallus gallus (Chicken) MNSVGEACTELKREYDQCFNRWFAEKFLKGENDGDPCGQLFKRYQLCVQKAIKEKDIPIEGLEFMGPSKGKAENSS 
XP_699741.1 zgc:112025 Danio rerio (Zebra fish) MNSVGEGCTELKREYDQCFNRWFAEKFLKGDRSADPCSELFNKYHTCVQKAIKEKDIPIEGVEFMGPNSEKADS-- 
 
 
Table 6.2 Full length amino acid sequences of P53CSV and its ortologs in eukaryotes* 
ID Gene Organism Sequence #AA 
O43715         TRIA1 Homo sapiens (human) 
----------MN-SVGEACTDMKREYDQCFNRWFAEKFLKGDSSG----
DPCTDLFKRYQQCVQKAIKEK---EIPIEGLE--FMG--------HGKEKPEN-
-SS---- 
76 
Q9D8Z2         TRIA1 Mus musculus (mouse) 
----------MN-SVGEACTDMKREYDQCFNRWFAEKFLKGDGSG----
DPCTDLFKRYQQCVQKAIKEK---EIPIEGLE--FMG--------HGKEKPEN-
-SS---- 
76 
Q6INR6         TRIAAA Xenopus laevis (African  frog) 
----------MN-SVGEECTDMKRDYDQCFNRWFAEKFLKGAGSG----
DPCTELFRRYRECVQKAIKDK---DIPVDGVD--FMG--------
PSKSKTESDGSS----   
78 
Q96VG1         YBAI S. pombe (fission yeast) 
----------MSSSVSEECTPAKKKYDACFNDWYANKFLKGDLHN----
RDCDELFAEYKSCLLKALKTK---KIDP-LLE---------------AARKED--------   69 
O60200         MDM35 S. cerevisiae (budding yeast) 
------ MGNIMSASFAPECTDLKTKYDSCFNEWYSEKFLKGKSVE----
NECSKQWYAYTTCVNAALVKQ---GIKPALDEAREEAP------
FENGGKLKEVDK-----   
86 
Q9SMZ9       Y4331 A. thalina (thale cress) 
MGLLKKKDSTSARSSTSPCADLRNAYHNCFNKWYSEKFVKGQWDK
----EECVAEWKKYRDCLSENLDGK---LLTRILEVDGELN--------
PTKQATDSKESSS--- 
92 
P45967           YNZ C. elegans 
-----MSDRHMS-SIFPECDHLKQIYDKCFTEFF-
QKFITPNYRHQYAVNPCERLHDVYKRCVEERLATQRPFEIDLDEIRK
EYLNTDDDKLKDRQNNQKTNSENKCSSS 
103 
 
 
*All amino acid sequences were obtained by E. Yague from Genbank   
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